Document:

EX-10.6

 Exhibit 10.6 
  

SOLID BIOSCIENCES INC. 

FORM OF 2018 OMNIBUS INCENTIVE PLAN 

 TABLE OF CONTENTS 

									
	 	 	 	 	 	  	Page	 
		
	ARTICLE I PURPOSE	  	 	1	 
		
	ARTICLE II DEFINITIONS	  	 	1	 
		 	2.1	 	 “Acquisition Event”
	  	 	1	 
		 	2.2	 	 “Affiliate”
	  	 	1	 
		 	2.3	 	 “Appreciation Award”
	  	 	1	 
		 	2.4	 	 “Award”
	  	 	2	 
		 	2.5	 	 “Board”
	  	 	2	 
		 	2.6	 	 “Cause”
	  	 	2	 
		 	2.7	 	 “Change in Control”
	  	 	2	 
		 	2.8	 	 “Change in Control Price”
	  	 	3	 
		 	2.9	 	 “Code”
	  	 	3	 
		 	2.10	 	 “Committee”
	  	 	3	 
		 	2.11	 	 “Common Stock”
	  	 	3	 
		 	2.12	 	 “Company”
	  	 	3	 
		 	2.13	 	 “Competitor”
	  	 	4	 
		 	2.14	 	 “Consultant”
	  	 	4	 
		 	2.15	 	 “Detrimental Activity”
	  	 	4	 
		 	2.16	 	 “Disability”
	  	 	5	 
		 	2.17	 	 “Disparagement”
	  	 	5	 
		 	2.18	 	 “Dividends”
	  	 	5	 
		 	2.19	 	 “Effective Date”
	  	 	5	 
		 	2.20	 	 “Eligible Employee”
	  	 	5	 
		 	2.21	 	 “Exchange Act”
	  	 	5	 
		 	2.22	 	 “Exercisable Awards”
	  	 	5	 
		 	2.23	 	 “Fair Market Value”
	  	 	6	 
		 	2.24	 	 “Family Member”
	  	 	6	 
		 	2.25	 	 “Incentive Stock Option”
	  	 	6	 
		 	2.26	 	 “Individual Target Award”
	  	 	6	 
		 	2.27	 	 “Lead Underwriter”
	  	 	6	 
		 	2.28	 	 “Lock-Up Period”
	  	 	6	 
		 	2.29	 	 “Non-Employee Director”
	  	 	6	 
		 	2.30	 	 “Non-Qualified Stock Option”
	  	 	6	 
		 	2.31	 	 “Other Extraordinary Event”
	  	 	6	 
		 	2.32	 	 “Other Stock-Based Award”
	  	 	6	 
		 	2.33	 	 “Parent”
	  	 	7	 
		 	2.34	 	 “Participant”
	  	 	7	 
		 	2.35	 	 “Performance-Based Cash Award”
	  	 	7	 
		 	2.36	 	 “Performance Criteria”
	  	 	7	 
		 	2.37	 	 “Performance Period”
	  	 	7	 
		 	2.38	 	 “Performance Share”
	  	 	7	 
		 	2.39	 	 “Performance Unit”
	  	 	7	 

  
 i 

									
		 	2.40	 	 “Person”
	  	 	7	 
		 	2.41	 	 “Plan”
	  	 	7	 
		 	2.42	 	 “Registration Date”
	  	 	7	 
		 	2.43	 	 “Restricted Stock”
	  	 	7	 
		 	2.44	 	 “Restriction Period”
	  	 	8	 
		 	2.45	 	 “Rule 13d-3”
	  	 	8	 
		 	2.46	 	 “Rule 16b-3”
	  	 	8	 
		 	2.47	 	 “Section 162(m)”
	  	 	8	 
		 	2.48	 	 “Section 4.2 Event”
	  	 	8	 
		 	2.49	 	 “Section 409A Covered Award”
	  	 	8	 
		 	2.50	 	 “Section 409A”
	  	 	8	 
		 	2.51	 	 “Securities Act”
	  	 	8	 
		 	2.52	 	 “Stock Option” or “Option”
	  	 	8	 
		 	2.53	 	 “Subsidiary”
	  	 	8	 
		 	2.54	 	 “Ten Percent Stockholder”
	  	 	8	 
		 	2.55	 	 “Termination”
	  	 	8	 
		 	2.56	 	 “Termination of Consultancy”
	  	 	8	 
		 	2.57	 	 “Termination of Directorship”
	  	 	9	 
		 	2.58	 	 “Termination of Employment”
	  	 	9	 
		 	2.59	 	 “Transfer”
	  	 	9	 
		 	2.60	 	 “Transition Period”
	  	 	9	 
		
	ARTICLE III ADMINISTRATION	  	 	10	 
		 	3.1	 	 The Committee
	  	 	10	 
		 	3.2	 	 Grant and Administration of Awards
	  	 	10	 
		 	3.3	 	 Award Agreements
	  	 	11	 
		 	3.4	 	 Guidelines
	  	 	11	 
		 	3.5	 	 Section 162(m)
	  	 	11	 
		 	3.6	 	 Delegation; Advisors
	  	 	11	 
		 	3.7	 	 Decisions Final
	  	 	11	 
		 	3.8	 	 Procedures
	  	 	12	 
		 	3.9	 	 Liability; Indemnification
	  	 	12	 
		
	ARTICLE IV SHARE LIMITATIONS	  	 	12	 
		 	4.1	 	 Shares
	  	 	12	 
		 	4.2	 	 Changes
	  	 	14	 
		 	4.3	 	 Minimum Purchase Price
	  	 	15	 
		
	ARTICLE V ELIGIBILITY	  	 	16	 
		 	5.1	 	 General Eligibility
	  	 	16	 
		 	5.2	 	 Incentive Stock Options
	  	 	16	 
		 	5.3	 	 General Requirement
	  	 	16	 

  
 ii 

									
		
	ARTICLE VI STOCK OPTIONS	  	 	16	 
		 	6.1	 	 Stock Options
	  	 	16	 
		 	6.2	 	 Incentive Stock Options
	  	 	17	 
		 	6.3	 	 Terms of Stock Options
	  	 	17	 
		
	ARTICLE VII RESTRICTED STOCK	  	 	20	 
		 	7.1	 	 Awards of Restricted Stock
	  	 	20	 
		 	7.2	 	 Awards and Certificates
	  	 	20	 
		 	7.3	 	 Restrictions and Conditions
	  	 	21	 
		
	ARTICLE VIII OTHER STOCK-BASED AWARDS	  	 	22	 
		 	8.1	 	 Other Awards
	  	 	22	 
		 	8.2	 	 Terms and Conditions
	  	 	23	 
		
	ARTICLE IX PERFORMANCE-BASED CASH AWARDS	  	 	24	 
		 	9.1	 	 Performance-Based Cash Awards
	  	 	24	 
		 	9.2	 	 Terms and Conditions
	  	 	25	 
		
	ARTICLE X CHANGE IN CONTROL PROVISIONS	  	 	27	 
		
	ARTICLE XI TERMINATION OR AMENDMENT OF PLAN	  	 	28	 
		
	ARTICLE XII UNFUNDED PLAN	  	 	28	 
		
	ARTICLE XIII GENERAL PROVISIONS	  	 	29	 
		 	13.1	 	 Legend
	  	 	29	 
		 	13.2	 	 Other Plans
	  	 	29	 
		 	13.3	 	 No Right to Employment, Consultancy, or Directorship
	  	 	29	 
		 	13.4	 	 Withholding of Taxes
	  	 	29	 
		 	13.5	 	 No Assignment of Benefits
	  	 	30	 
		 	13.6	 	 Listing and Other Conditions
	  	 	30	 
		 	13.7	 	 Governing Law
	  	 	30	 
		 	13.8	 	 Construction
	  	 	30	 
		 	13.9	 	 No Acquired Rights
	  	 	31	 
		 	13.10	 	 Data Protection
	  	 	31	 
		 	13.11	 	 Costs
	  	 	31	 
		 	13.12	 	 No Right to Same Benefits
	  	 	31	 
		 	13.13	 	 Death or Disability
	  	 	31	 
		 	13.14	 	 Section 16(b) of the Exchange Act
	  	 	32	 
		 	13.15	 	 Section 409A
	  	 	32	 
		 	13.16	 	 Successor and Assigns
	  	 	33	 
		 	13.17	 	 Severability of Provisions
	  	 	33	 
		 	13.18	 	 Participants Subject to Taxation Outside the U.S.; No Tax Equalization
	  	 	33	 

  
 iii 

									
		 	13.19	 	 Payments to Minors, Etc
	  	 	33	 
		 	13.20	 	 Headings and Captions
	  	 	33	 
		 	13.21	 	 Recoupment
	  	 	34	 
		 	13.22	 	 Reformation
	  	 	34	 
		 	13.23	 	 Electronic Communications
	  	 	34	 
		 	13.24	 	 Agreement
	  	 	34	 
		 	13.25	 	 Transition Period
	  	 	34	 
		
	ARTICLE XIV EFFECTIVE DATE OF PLAN	  	 	35	 
		
	ARTICLE XV TERM OF PLAN	  	 	35	 
		
	EXHIBIT A: PERFORMANCE CRITERIA	  	 	Ex. A-1	 
	EXHIBIT B: UNITED KINGDOM ADDENDUM	  	 	Ex. B-1	 
		 	1.	 	 Purpose
	  	 	Ex. B-1	 
		 	2.	 	 Definitions
	  	 	Ex. B-1	 
		 	3.	 	 Terms
	  	 	Ex. B-1	 
		 	4.	 	 Withholding Obligations
	  	 	Ex. B-1	 
		 	5.	 	 Section 431 Elections
	  	 	Ex. B-2	 

  
 iv 

 SOLID BIOSCIENCES INC. 

2018 OMNIBUS INCENTIVE PLAN 

ARTICLE I  
 PURPOSE

 The purpose of this Solid Biosciences Inc. 2018 Omnibus Incentive Plan is to enhance the profitability and value of the Company for
the benefit of its stockholders by enabling the Company to offer Eligible Employees, Consultants, and Non-Employee Directors incentive awards to attract, retain, and reward such individuals and strengthen the
mutuality of interests between such individuals and the Company’s stockholders. The Plan, as set forth herein, is effective as of the Effective Date (as defined in Article XIV). 

ARTICLE II 
 DEFINITIONS

 For purposes of the Plan, the following terms shall have the following meanings: 

2.1 “Acquisition Event” 

means a merger or consolidation in which the Company is not the surviving entity, any transaction that results in the acquisition of all or
substantially all of the Company’s outstanding Common Stock by a single person or entity or by a group of persons or entities acting in concert, or the sale or transfer of all or substantially all of the Company’s assets. 

2.2 “Affiliate” 

means each of the following: (a) any Subsidiary; (b) any Parent; (c) any corporation, trade, or business (including a
partnership or limited liability company) that is directly or indirectly controlled 50% or more (whether by ownership of stock, assets, or an equivalent ownership interest or voting interest) by the Company or any Affiliate; (d) any
corporation, trade, or business (including a partnership or limited liability company) that directly or indirectly controls 50% or more (whether by ownership of stock, assets, or an equivalent ownership interest or voting interest) of the Company;
and (e) any other entity in which the Company or any Affiliate has a material equity interest and that is designated as an “Affiliate” by resolution of the Committee. 

2.3 “Appreciation Award” 

means any Stock Option or any Other Stock-Based Award that is based on the appreciation in value of a
share of Common Stock in excess of an amount at least equal to the Fair Market Value on the date such Stock Option or Other Stock-Based Award is granted. 

  
 1 

 2.4 “Award” 

means any award granted or made under the Plan of any Stock Option, Restricted Stock, Other
Stock-Based Award, or Performance-Based Cash Award. 

2.5 “Board” 

means the Board of Directors of the Company. 

2.6 “Cause” 

means, with respect to a Participant’s Termination of Employment or Termination of Consultancy, unless otherwise defined in the
applicable Award agreement or other written agreement approved by the Committee, a termination due to (i) the failure by the Participant to perform such duties as are reasonably requested by the Company; (ii) the Participant’s
disregard of his or her duties or failure to act, where such action would be in the ordinary course of the Participant’s duties; (iii) the failure by the Participant to observe policies of the Company or any Affiliate generally applicable
to employees of the Company or any Affiliate; (iv) the gross negligence or willful misconduct by the Participant in the performance of his or her duties; (v) the commission by the Participant of any act of fraud, theft, dishonesty, or
self-dealing with respect to the Company or any Affiliate, or any felony or criminal act involving moral turpitude; (vi) the Participant’s conviction of, or plea of guilty or nolo contendere to, a felony; (vii) any breach by the
Participant of the provisions of any confidentiality, non-competition, or non-solicitation agreement between the Participant and the Company or any Affiliate, or any other agreement or contract with the
Company or any Affiliate; (viii) chronic absenteeism (excluding vacations, illnesses, or leaves of absence approved by the Company); (ix) any alcohol or other substance abuse by the Participant; or (x) the commission by the
Participant of any violation of any state or federal law relating to the workplace environment (including, without limitation, laws relating to sexual harassment or age, sex, or other prohibited discrimination). With respect to a Participant’s
Termination of Directorship, “cause” means an act or failure to act that constitutes cause for removal of a director under Delaware law. 

2.7 “Change in Control” 

unless otherwise defined in the applicable Award agreement or other written agreement approved by the Committee and subject to
Section 13.15(b), means the occurrence of any of the following: 
 (a) the acquisition (including through purchase, reorganization,
merger, consolidation, or similar transaction), directly or indirectly, in one or more transactions by a Person (other than any Person or group of Persons consisting solely of stockholders of the Company as of the date immediately before the
Registration Date) of beneficial ownership (within the meaning of Rule 13d-3) of securities representing 50% or more of the combined voting power of the securities of the Company entitled to vote
generally in the election of directors, calculated on a fully diluted basis after giving effect to such acquisition; 
 (b) an election of
Persons to the Board that causes two-thirds of the Board to consist of Persons other than (i) members of the Board on the Effective Date and (ii) Persons who were nominated for election as members of
the Board at a time when two-thirds of the Board consisted of Persons who were members of the Board on the Effective Date; provided that any Person nominated for election by a Board at least two-thirds of which consisted of Persons described in clauses (i) or (ii) or by Persons who were themselves nominated by such Board shall be deemed to have been nominated by a Board consisting of Persons
described in clause (i); or 

  
 2 

 (c) the sale or other disposition, directly or indirectly, of all or substantially all of the
assets of the Company and its subsidiaries, taken as a whole, to any Person (other than any Person or group of Persons consisting solely of stockholders of the Company as of the date immediately before the Registration Date); 

provided, however, that a Change in Control shall be deemed to not have occurred if such Change in Control results from the issuance, in
connection with a bona fide transaction or series of transactions with the primary purpose of providing equity financing to the Company or any of its Affiliates, of voting securities of the Company or any of its Affiliates or any rights to acquire
voting securities of the Company or any of its Affiliates that are convertible into voting securities. 
 2.8 “Change in Control
Price” 
 has the meaning set forth in Section 10.1. 

2.9 “Code” 

means the Internal Revenue Code of 1986, as amended, and all rules and regulations promulgated thereunder. Any reference to any Section of the
Code shall also be a reference to any successor provision. 
 2.10 “Committee” 

means: (a) with respect to the application of the Plan to Eligible Employees and Consultants, the Compensation Committee of the Board or
such other committee or subcommittee that is appointed by the Board, in each case, consisting of two or more non-employee directors, each of whom is intended to be (i) to the extent required by Rule 16b-3, a Non-Employee Director; (ii) to the extent required by Section 162(m), an “outside director” as defined under Section 162(m); and
(iii) as applicable, an “independent director” as defined under the Nasdaq Listing Rules, the NYSE Listed Company Manual, or other applicable stock exchange rules; and (b) with respect to the application of the Plan to Non-Employee Directors, the Board. It is intended that, absent an affirmative decision by the Board to appoint a separate Committee, the Compensation Committee of the Board shall serve as the “Committee”
with respect to the application of the Plan to Eligible Employees and Consultants. To the extent that no Committee exists that has the authority to administer the Plan, the functions of the Committee shall be exercised by the Board, and all
references herein to the Committee shall be deemed references to the Board. If for any reason the appointed Committee does not meet the requirements of Rule 16b-3 or Section 162(m), such
noncompliance shall not affect the validity of Awards, grants, interpretations, or other actions of the Committee. 
 2.11
“Common Stock” 
 means the common stock of the Company, par value $0.001 per share. 

2.12 “Company” 

means Solid Biosciences Inc., a Delaware corporation, and its successors by operation of law. 

  
 3 

 2.13 “Competitor” 

means any Person that is, directly or indirectly, in competition with the business or activities of the Company and its Affiliates. 

2.14 “Consultant” 

means any natural person who provides bona fide consulting or advisory services to the Company or its Affiliates, provided that
such services are not in connection with the offer or sale of securities in a capital-raising transaction, and do not, directly or indirectly, promote or maintain a market for the Company’s or its
Affiliates’ securities. 
 2.15 “Detrimental Activity” 

means, unless otherwise defined in the applicable Award agreement or other written agreement approved by the Committee: 

(a) without written authorization from the Company, disclosure to any Person outside the Company and its Affiliates or the use in any manner,
except as necessary in the furtherance of the Participant’s responsibilities to the Company or any of its Affiliates, at any time, of any confidential information, trade secrets, or proprietary information relating to the business of the
Company or any of its Affiliates that is acquired by the Participant at any time before the Participant’s Termination; 
 (b) any
activity while employed or performing services that results, or if known could have reasonably been expected to result, in the Participant’s Termination for Cause; 

(c) without written authorization from the Company, directly or indirectly, in any capacity whatsoever, (i) owning, managing, operating,
controlling, being employed by (whether as an employee, consultant, independent contractor, or otherwise, and whether or not for compensation), or rendering services to any Competitor; (ii) soliciting, aiding, or inducing any customer of the
Company or any Subsidiary to curtail, reduce, or terminate its business relationship with the Company or any Subsidiary, or in any other way interfering with any such business relationships with the Company or any Subsidiary; (iii) soliciting,
aiding, or inducing any employee, representative, or agent of the Company or any Subsidiary to leave such employment or retention or to accept employment with or render services to or with any other person, firm, corporation, or other entity
unaffiliated with the Company or hiring or retaining any such employee, representative, or agent or taking any action to materially assist or aid any other person, firm, corporation, or other entity in identifying, hiring, or soliciting any such
employee, representative, or agent; or (iv) interfering, or aiding, or inducing any other person or entity in interfering with the relationship between the Company, its Subsidiaries, and any of their respective vendors, joint venturers, or
licensors; 
 (d) a material breach of any restrictive covenant contained in any agreement between the Participant and the Company or an
Affiliate; or 
 (e) the Participant’s Disparagement, or inducement of other to do so, of the Company or its Affiliates or their past or
present officers, directors, employees, or products. 
 Only the Chief Executive Officer or the Chief Financial Officer of the Company (or their designee,
as evidenced in writing) shall have the authority to provide the Participant, except for himself or herself, with written authorization to engage in the activities contemplated in subsections (a) and (c). 

  
 4 

 2.16 “Disability” 

means, unless otherwise defined in the applicable Award agreement or other written agreement approved by the Committee, with respect to
a Participant’s Termination, a “permanent and total disability,” as defined in Section 22(e)(3) of the Code. A Disability shall only be deemed to occur at the time of the determination by the Committee of the Disability.
Notwithstanding the foregoing, for an Award that provides for payment or settlement triggered upon a Disability and that constitutes a Section 409A Covered Award, the foregoing definition shall apply for purposes of vesting of such Award,
provided that for purposes of payment or settlement of such Award, such Award shall not be paid (or otherwise settled) until the earliest of: (A) the Participant’s “disability” within the meaning of
Section 409A(a)(2)(C) of the Code, (B) the Participant’s “separation from service” within the meaning of Section 409A of the Code, and (C) the date such Award would otherwise be settled pursuant to the terms of the
Award agreement. 
 2.17 “Disparagement” 

means making comments or statements to the press, the Company’s or its Affiliates’ employees, consultants, or any individual or
entity with whom the Company or its Affiliates has a business relationship that could reasonably be expected to adversely affect in any manner: (a) the conduct of the business of the Company or its Affiliates (including, without limitation, any
products or business plans or prospects); or (b) the business reputation of the Company or its Affiliates, or any of their products, or their past or present officers, directors, or employees. For purposes of this Section 2.17,
“Disparagement” does not include (i) compliance with legal process or subpoenas to the extent only truthful statements are rendered in such compliance attempt, (ii) statements made in response to an inquiry from a court or
regulatory body, or (iii) reporting possible violations of federal law or regulation to any governmental agency or entity, including but not limited to, the Department of Justice, the Securities and Exchange Commission, the U.S. Congress, or
any Inspector General, or making other disclosures that are protected under the whistleblower provisions of applicable law or regulation. 

2.18 “Dividends” 

means dividends, dividend equivalents, or other distributions. 

2.19 “Effective Date” 

means the effective date of the Plan, as defined in Article XIV. 

2.20 “Eligible Employee” 

means an employee of the Company or an Affiliate. 

2.21 “Exchange Act” 

means the Securities Exchange Act of 1934, as amended, and all rules and regulations promulgated thereunder. Any references to any Section of
the Exchange Act shall also be a reference to any successor provision. 
 2.22 “Exercisable Awards” 

has the meaning set forth in Section 4.2(d). 

  
 5 

 2.23 “Fair Market Value” 

unless otherwise required by any applicable provision of the Code, means as of any date and except as provided below, (a) the closing
price reported for the Common Stock on such date: (i) as reported on the principal national securities exchange in the United States on which it is then traded, or (ii) if not traded on any such national securities exchange, as quoted on
an automated quotation system sponsored by the Financial Industry Regulatory Authority; or (b) if the Common Stock shall not have been reported or quoted on such date, on the first day prior thereto on which the Common Stock was reported or
quoted. If the Common Stock is not traded, listed, or otherwise reported or quoted, then Fair Market Value means the fair market value of the Common Stock as determined by the Committee in good faith in whatever manner it considers appropriate,
taking into account the requirements of Section 409A or Section 422 of the Code, as applicable. Notwithstanding anything herein to the contrary, for purposes of any Stock Options that are granted effective on the Registration Date, the
Fair Market Value shall equal the initial public offering price of the Common Stock. 
 2.24 “Family Member” 

means “family member,” as defined in Section A.1.(a)(5) of the general instructions of Form
S-8, as may be amended from time to time. 
 2.25 “Incentive Stock Option”

 means any Stock Option awarded to an Eligible Employee of the Company, its Subsidiaries, or its Parent intended to be and designated
as an “Incentive Stock Option” within the meaning of Section 422 of the Code. 
 2.26 “Individual Target
Award” 
 has the meaning in Section 9.1. 

2.27 “Lead Underwriter” 

has the meaning in Section 13.24. 

2.28 “Lock-Up Period” 

has the meaning in Section 13.24. 

2.29 “Non-Employee Director” 

means a “non-employee director,” as defined in
Rule 16b-3. 
 2.30 “Non-Qualified Stock
Option” 
 means any Stock Option that is not an Incentive Stock Option. 

2.31 “Other Extraordinary Event” 

has the meaning in Section 4.2(b). 

2.32 “Other Stock-Based Award” 

means an Award under Article VIII that is valued in whole or in part by reference to, or is payable in or otherwise based on, Common
Stock. 

  
 6 

 2.33 “Parent” 

means any “parent corporation” of the Company within the meaning of Section 424(e) of the Code. 

2.34 “Participant” 

means an Eligible Employee, Non-Employee Director, or Consultant to whom an Award has been granted
pursuant to the Plan. 
 2.35 “Performance-Based Cash Award” 

means a cash Award under Article IX that is payable or otherwise based on the attainment of certain
pre-established performance goals during a Performance Period. 
 2.36 “Performance
Criteria” 
 has the meaning set forth in Exhibit A. 

2.37 “Performance Period” 

means each fiscal year of the Company or such other period (as specified by the Committee) over which the attainment of performance goals is
measured. 
 2.38 “Performance Share” 

means an Other Stock-Based Award of the right to receive a number of shares of Common Stock or cash of
an equivalent value at the end of a specified Performance Period. 
 2.39 “Performance Unit” 

means an Other Stock-Based Award of the right to receive a fixed dollar amount, payable in cash or
Common Stock or a combination of both, at the end of a specified Performance Period. 
 2.40 “Person” 

means any individual, entity (including any employee benefit plan or any trust for an employee benefit plan), or group (within the meaning of
Section 13(d)(3) or Section 14(d)(2) of the Exchange Act, or any successor provision). 
 2.41 “Plan” 

means this Solid Biosciences Inc. 2018 Omnibus Incentive Plan, as amended from time to time. 

2.42 “Registration Date” 

means the first date on or after the Effective Date (a) on which the Company sells its Common Stock in a bona fide, firm
commitment underwriting pursuant to a registration statement under the Securities Act, or (b) any class of common equity securities of the Company is required to be registered under Section 12 of the Exchange Act. 

2.43 “Restricted Stock” 

means an Award of shares of Common Stock that is subject to restrictions pursuant to Article VII. 

  
 7 

 2.44 “Restriction Period” 

has the meaning set forth in Section 7.3(a). 

2.45 “Rule 13d-3” 

means Rule 13d-3 under Section 13(d) of the Exchange Act as then in effect or any successor
provision and all rules and regulations promulgated thereunder. 
 2.46
“Rule 16b-3” 
 means
Rule 16b-3 under Section 16(b) of the Exchange Act as then in effect or any successor provision and all rules and regulations promulgated thereunder. 

2.47 “Section 162(m)” 

means the exception for performance-based compensation under Section 162(m) of the Code and all
rules and regulations promulgated thereunder. 
 2.48 “Section 4.2 Event” 

has the meaning set forth in Section 4.2(b). 

2.49 “Section 409A Covered Award” 

has the meaning set forth in Section 13.15. 

2.50 “Section 409A” 

means the nonqualified deferred compensation rules under Section 409A of the Code and all rules and regulations promulgated thereunder.

 2.51 “Securities Act” 

means the Securities Act of 1933, as amended, and all rules and regulations promulgated thereunder. Any reference to any Section of the
Securities Act shall also be a reference to any successor provision. 
 2.52 “Stock Option” or “Option”

 means any option to purchase shares of Common Stock granted pursuant to Article VI. 

2.53 “Subsidiary” 

means any “subsidiary corporation” of the Company within the meaning of Section 424(f) of the Code. 

2.54 “Ten Percent Stockholder” 

means a person owning stock possessing more than 10% of the total combined voting power of all classes of stock of the Company, its
Subsidiaries, or its Parent. 
 2.55 “Termination” 

means a Termination of Consultancy, Termination of Directorship, or Termination of Employment, as applicable. 

2.56 “Termination of Consultancy” 

means: (a) that the Consultant is no longer acting as a consultant to the Company or an Affiliate; or (b) when an entity that is
retaining a Participant as a Consultant ceases to be an 

  
 8 

 
Affiliate, unless the Participant otherwise is, or thereupon becomes, a Consultant to the Company or another Affiliate at the time the entity ceases to be an Affiliate. In the event that a
Consultant becomes an Eligible Employee or a Non-Employee Director upon the termination of his consultancy, unless otherwise determined by the Committee, no Termination of Consultancy shall be deemed to occur
until such time as such Consultant is no longer a Consultant, an Eligible Employee, or a Non-Employee Director. Notwithstanding the foregoing, the Committee may otherwise define Termination of Consultancy in
the Award agreement or, if no rights of a Participant are reduced, may otherwise define Termination of Consultancy thereafter. 
 2.57
“Termination of Directorship” 
 means that the Non-Employee Director has
ceased to be a director of the Company; except that if a Non-Employee Director becomes an Eligible Employee or a Consultant upon the termination of his directorship, his ceasing to be a director of the Company
shall not be treated as a Termination of Directorship unless and until the Participant has a Termination of Employment or Termination of Consultancy, as the case may be. 

2.58 “Termination of Employment” 

means: (a) a termination of employment (for reasons other than a military or other approved leave of absence) of a Participant from the
Company and its Affiliates; or (b) when an entity that is employing a Participant ceases to be an Affiliate, unless the Participant otherwise is, or thereupon becomes, employed by the Company or another Affiliate at the time the entity ceases
to be an Affiliate. In the event that an Eligible Employee becomes a Consultant or a Non-Employee Director upon the termination of his employment, unless otherwise determined by the Committee, no Termination
of Employment shall be deemed to occur until such time as such Eligible Employee is no longer an Eligible Employee, a Consultant, or a Non-Employee Director. Notwithstanding the foregoing, the Committee may
otherwise define Termination of Employment in the Award agreement or, if no rights of a Participant are reduced, may otherwise define Termination of Employment thereafter. 

2.59 “Transfer” 

means: (a) when used as a noun, any direct or indirect transfer, offer, sale, assignment, pledge, lease, donation, grant, gift, bequest,
hypothecation, encumbrance, charge, or other disposition (including the issuance of equity in a Person), whether for value or no value and whether voluntary or involuntary (including by operation of law), and (b) when used as a verb, to
directly or indirectly transfer, offer, sell, assign, pledge, lease, donate, grant, gift, bequest, hypothecate, encumber, charge, or otherwise dispose of (including the issuance of equity in a Person) whether for value or for no value and whether
voluntarily or involuntarily (including by operation of law). “Transferred” and “Transferable” shall have a correlative meaning. 

2.60 “Transition Period” 

means the “reliance period” under Treasury Regulation Section 1.162-27(f)(2), which
ends on the earliest to occur of the following: (i) the date of the first annual meeting of stockholders at which directors are to be elected that occurs after the close of the third calendar year following the calendar year in which the
Registration Date occurs; (ii) the date the Plan is materially amended for purposes of Treasury Regulation Section 1.162-27(h)(1)(iii); or (iii) the date all shares of Common Stock available for
issuance under the Plan have been allocated. 

  
 9 

 ARTICLE III  

ADMINISTRATION 
 3.1
The Committee. 
 The Plan shall be administered and interpreted by the Committee. 

3.2 Grant and Administration of Awards. 

The Committee shall have full authority and discretion, as provided in Section 3.7, to grant and administer Awards, including the
authority to: 
 (a) select the Eligible Employees, Consultants, and Non-Employee Directors to whom
Awards may from time to time be granted; 
 (b) determine the number of shares of Common Stock to be covered by each Award; 

(c) determine the type and the terms and conditions, not inconsistent with the terms of the Plan, of each Award (including the exercise or
purchase price (if any), any restriction, forfeiture, or limitation, and any vesting schedule or acceleration or waiver thereof); 
 (d)
determine whether a Stock Option is an Incentive Stock Option or Non-Qualified Stock Option; 
 (e)
determine whether to require a Participant, as a condition of the granting of any Award, to refrain from selling or otherwise disposing of Common Stock acquired pursuant to such Award for a period of time, as determined by the Committee; 

(f) condition the grant, vesting, or payment of any Award on the attainment of performance goals (including goals based on the Performance
Criteria) over a Performance Period, set such goals and such period, and certify the attainment of such goals; 
 (g) amend, after the date
of grant, the terms that apply to an Award upon a Participant’s Termination, provided that such amendment does not reduce the Participant’s rights under the Award; 

(h) adopt, alter, or repeal such subplans to the Plan as it shall deem necessary or advisable; 

(i) determine the circumstances under which Common Stock and other amounts payable with respect to an Award may be deferred automatically or at
the election of the Participant, in each case in a manner intended to comply with or be exempt from Section 409A; 
 (j) generally,
exercise such powers and perform such acts as the Committee deems necessary or advisable to promote the best interests of the Company in connection with the Plan that are not inconsistent with the provisions of the Plan and applicable law; 

(k) construe and interpret the terms and provisions of the Plan and any Award (and any agreements relating thereto); and 

(l) correct any defect, supply any omission, or reconcile any inconsistency in the Plan or in any agreement relating thereto. 

  
 10 

 3.3 Award Agreements. 

All Awards shall be evidenced by, and subject to the terms and conditions of, a written notice provided by the Company to the Participant or a
written agreement executed by the Company and the Participant. 
 3.4 Guidelines. 

The Committee shall have the authority to adopt, alter, and repeal such administrative rules, guidelines, and practices governing the Plan as
it shall, from time to time, deem necessary or advisable. The Committee may adopt special guidelines and provisions for persons who are residing in or employed in, or subject to, the taxes of, any domestic or foreign jurisdiction to comply with
applicable tax and securities laws and may impose such limitations and restrictions that it deems necessary or advisable to comply with the applicable tax and securities laws of such domestic or foreign jurisdiction. 

3.5 Section 162(m). 

Notwithstanding anything herein to the contrary, with regard to any provision of the Plan or any agreement relating thereto that is intended
to comply with Section 162(m) following the Transition Period, any action or determination by the Committee shall be permitted only to the extent such action or determination would be permitted under Section 162(m). The Plan has been
adopted by the Board before the Registration Date and is intended to rely on the Transition Period and, following the Transition Period with respect to Awards intended to be “performance-based,” to
comply with the applicable provisions of Section 162(m), and the Plan shall be limited, construed, and interpreted in a manner so as to comply therewith. 

3.6 Delegation; Advisors. 

The Committee may, as it from time to time deems advisable and to the extent permitted by applicable law and stock exchange rules: 

(a) delegate its responsibilities to officers or employees of the Company and its Affiliates, including delegating authority to officers to
grant Awards or execute agreements or other documents on behalf of the Committee; and 
 (b) engage legal counsel, consultants, professional
advisors, and agents to assist in the administration of the Plan and rely upon any opinion or computation received from any such Person. Expenses incurred by the Committee or the Board in the engagement of any such person shall be paid by the
Company. 
 3.7 Decisions Final. 

All determinations, evaluations, elections, approvals, authorizations, consents, decisions, interpretations, and other actions made or taken
by or at the direction of the Company, the Board, or the Committee (or any of its members) arising out of or in connection with the Plan shall be within the sole and absolute discretion of all and each of them, and shall be final, binding, and
conclusive on all employees and Participants and their respective beneficiaries, heirs, executors, administrators, successors, and assigns. 

  
 11 

 3.8 Procedures. 

If the Committee is appointed, the Board shall designate one of the members of the Committee as chairperson, and the Committee shall hold
meetings, subject to the By-Laws of the Company, at such times and places as it shall deem advisable, including by telephone conference or by written consent to the extent permitted by applicable law. A
majority of the Committee members shall constitute a quorum. All determinations of the Committee shall be made by a majority of its members. Any decision or determination reduced to writing and signed by all of the Committee members in accordance
with the By-Laws of the Company shall be fully effective as if it had been made by a vote at a meeting duly called and held. The Committee shall keep minutes of its meetings and shall make such rules and
regulations for the conduct of its business as it shall deem advisable. 
 3.9 Liability; Indemnification. 

(a) The Committee, its members, and any delegate or Person engaged pursuant to Section 3.6 shall not be liable for any action or
determination made in good faith with respect to the Plan. To the maximum extent permitted by applicable law, no officer or employee of the Company or any Affiliate or member or former member of the Committee or of the Board shall be liable for any
action or determination made in good faith with respect to the Plan or any Award granted under it. 
 (b) To the maximum extent permitted by
applicable law and the Certificate of Incorporation and By-Laws of the Company and to the extent not covered by insurance directly insuring such person, each current or former officer or employee of the
Company or any Affiliate and member of the Committee or the Board shall be indemnified and held harmless by the Company against any cost or expense (including reasonable fees of counsel reasonably acceptable to the Committee) or liability (including
any sum paid in settlement of a claim with the approval of the Committee), and shall be advanced amounts necessary to pay the foregoing at the earliest time and to the fullest extent permitted, arising out of any act or omission to act in connection
with the administration of the Plan, except to the extent arising out of such person’s own fraud or bad faith. Such indemnification shall be in addition to any rights of indemnification provided for under applicable law or under the Certificate
of Incorporation or By-Laws of the Company or any Affiliate. Notwithstanding anything herein to the contrary, this indemnification will not apply to the actions or determinations made by an individual with
regard to Awards granted to him. 
 ARTICLE IV  

SHARE LIMITATIONS 
 4.1
Shares. 
 (a) General Limitations. 

(i) Subject to Section 4.2, the aggregate number of shares of Common Stock which may be issued or used for reference purposes or with
respect to which Awards under the Plan may be granted over the term of the Plan is 4,835,000. Subject to Section 4.2, no more than 4,835,000 shares of Common Stock in the aggregate may be issued under the Plan in respect of Incentive Stock
Options. At all times, the Company will reserve and keep available a sufficient number of shares of Common Stock as will be required to satisfy the requirements of all Awards granted and outstanding under the Plan. 

  
 12 

 (ii) If any Appreciation Award expires, terminates, or is canceled for any reason without having
been exercised in full, the number of shares of Common Stock underlying any unexercised portion shall again be available under the Plan. If shares of Restricted Stock or Other Stock-Based Awards that are not
Appreciation Awards are forfeited for any reason, the number of forfeited shares comprising or underlying the Award shall again be available under the Plan. 

(iii) The number of shares of Common Stock available under the Plan shall be reduced by (A) the total number of Appreciation Awards that
have been exercised, regardless of whether any shares of Common Stock underlying such Awards are actually issued to the Participant as the result of a net exercise or settlement, and (B) all shares of Common Stock, not covered by
clause (A) above used to pay any exercise price or tax withholding obligation with respect to any Award. In addition, the Company may not use the cash proceeds it receives from Stock Option exercises to repurchase shares of Common Stock on the
open market for reuse under the Plan. Notwithstanding anything to the contrary herein, Awards that may be settled solely in cash shall not be deemed to use any shares under the Plan. 

(iv) Shares issued under the Plan may be either authorized and unissued Common Stock or Common Stock held in or acquired for the treasury of
the Company, or both. 
 (b) Individual Participant Limitations. Except as otherwise provided herein, at all times after the end of
the Transition Period: 
 (i) the maximum number of shares of Common Stock that may be made subject to Stock Options, Restricted Stock, or
Other Stock-Based Awards denominated in shares of Common Stock granted to each Eligible Employee or Consultant during any fiscal year of the Company is 2,417,500 shares per type of Award (subject to increase
or decrease pursuant to Section 4.2); 

  
 13 

 (ii) the aggregate amount of compensation to be paid to any one Participant in respect of all
Other Stock-Based Awards denominated in dollars and Performance-Based Cash Awards, and granted to such Participant in any one fiscal year of the Company, shall not
exceed $5 million, and any Awards that are cancelled during the year shall be counted against this limit to the extent required by Section 162(m) of the Code; provided, further, that the foregoing limit shall be adjusted on a
proportionate basis for any Performance Period that is not based on one fiscal year of the Company; and 
 (iii) the maximum number of
shares of Common Stock that may be made subject to Awards granted to each Non-Employee Director during any fiscal year of the Company is 967,000 shares (subject to increase or decrease pursuant to
Section 4.2); and 
 provided, however, that the foregoing individual Participant limits shall not apply to (x) any Awards granted at any
time that are not intended to be “performance-based” under Section 162(m) of the Code, and (y) the following Awards granted at any time during the Transition Period: (A) Options or
Other Stock-Based Awards that are stock appreciation rights, and (B) Restricted Stock or Other Stock-Based Awards that constitute “restricted property”
under Section 83 of the Code to the extent granted during the Transition Period, even if such Awards vest or are settled after the Transition Period. 

4.2 Changes. 
 (a)
The existence of the Plan and the Awards shall not affect in any way the right or power of the Board or the stockholders of the Company to make or authorize (i) any adjustment, recapitalization, reorganization, or other change in the
Company’s capital structure or its business, (ii) any merger or consolidation of the Company or any Affiliate, (iii) any issuance of bonds, debentures, or preferred or prior preference stock ahead of or affecting the Common Stock,
(iv) the dissolution or liquidation of the Company or any Affiliate, (v) any sale or transfer of all or part of the assets or business of the Company or any Affiliate, (vi) any Section 4.2 Event, or (vii) any other corporate
act or proceeding. 
 (b) Subject to the provisions of Section 4.2(d), in the event of any change in the capital structure or business
of the Company by reason of any stock split, reverse stock split, stock dividend, combination or reclassification of shares, recapitalization, merger, consolidation, spin off, split off, reorganization or partial or complete liquidation, issuance of
rights or warrants to purchase Common Stock or securities convertible into Common Stock, sale or transfer of all or part of the Company’s assets or business, or other corporate transaction or event that would be considered an “equity
restructuring” within the meaning of FASB ASC Topic 718 (each, a “Section 4.2 Event”), then (i) the aggregate number or kind of shares that thereafter may be issued under the Plan, (ii) the number or kind
of shares or other property (including cash) subject to an Award, (iii) the purchase or exercise price of Awards, and (iv) the individual Participant limits set forth in Section 4.1(b) (other than cash limitations) shall be adjusted
by the Committee as the Committee determines, in good faith, to be necessary or advisable to prevent substantial dilution or enlargement of the rights of the Participants under the Plan. In connection with any Section 4.2 Event, the Committee
may provide for the cancellation of outstanding Awards and payment in cash or other property in exchange therefor. In addition, subject to Section 4.2(d), in the event of any change in the capital structure of the Company that is not a
Section 4.2 Event (an “Other Extraordinary Event”), then the Committee may make the adjustments described in 

  
 14 

 
clauses (i) through (iv) above as it determines, in good faith, to be necessary or advisable to prevent substantial dilution or enlargement of the rights of Participants under the Plan.
Notice of any such adjustment shall be given by the Committee, or otherwise be made available, to each Participant whose Award has been adjusted and such adjustment (whether or not such notice is given) shall be binding for all purposes of the Plan.
Except as expressly provided in this Section 4.2(b) or in the applicable Award agreement, a Participant shall have no rights by reason of any Section 4.2 Event or any Other Extraordinary Event. Notwithstanding the foregoing, (x) any
adjustments made pursuant to Section 4.2(b) to Awards that are considered “non-qualified deferred compensation” within the meaning of Section 409A shall be made in a manner intended to
comply with the requirements of Section 409A; and (y) any adjustments made pursuant to Section 4.2(b) to Awards that are not considered “non-qualified deferred compensation” subject to
Section 409A shall be made in a manner intended to ensure that after such adjustment, the Awards either (A) continue to be exempt from Section 409A or (B) comply with the requirements of Section 409A. 

(c) Fractional shares of Common Stock resulting from any adjustment in Awards pursuant to Section 4.2(a) or (b) shall be aggregated
until, and eliminated at, the time of exercise by rounding-down for fractions less than one-half and rounding-up for fractions
equal to or greater than one-half. No cash settlements shall be made with respect to fractional shares eliminated by rounding. 

(d) Upon the occurrence of an Acquisition Event, the Committee may terminate all outstanding and unexercised Stock Options or any Other Stock-Based Award that provides for a Participant-elected exercise (collectively, “Exercisable Awards”), effective as of the date of the Acquisition
Event, by delivering notice of termination to each Participant at least 20 days before the date of consummation of the Acquisition Event, in which case during the period from the date on which such notice of termination is delivered to the
consummation of the Acquisition Event, each such Participant shall have the right to exercise in full all of such Exercisable Awards that are then outstanding to the extent vested on the date such notice of termination is given (or, at the
discretion of the Committee, without regard to any limitations on exercisability otherwise contained in the Award agreements), but any such exercise shall be contingent on the occurrence of the Acquisition Event, and, provided that, if the
Acquisition Event does not take place within a specified period set forth in such notice, if any, for any reason whatsoever, the notice and exercise pursuant thereto shall be null and void and the applicable provisions of Section 4.2(b) and
Article X shall apply. For the avoidance of doubt, in the event of an Acquisition Event, the Committee may terminate any Exercisable Award for which the exercise price is equal to or exceeds the Fair Market Value on the date of the Acquisition
Event without payment of consideration therefor. If an Acquisition Event occurs but the Committee does not terminate the outstanding Awards pursuant to this Section 4.2(d), then the provisions of Section 4.2(b) and Article X shall
apply. 
 4.3 Minimum Purchase Price. 

Notwithstanding anything herein to the contrary, if authorized but previously unissued shares of Common Stock are issued under the Plan, such
shares shall not be issued for consideration that is less than required under applicable law. 

  
 15 

 ARTICLE V 

ELIGIBILITY 
 5.1
General Eligibility. 
 All current and prospective Eligible Employees and Consultants, and current Non-Employee Directors, are eligible to be granted Awards. Eligibility for the grant of Awards and actual participation in the Plan shall be determined by the Committee in its sole discretion. Notwithstanding
anything herein to the contrary, no Award under which a Participant may receive shares of Common Stock may be granted to an Eligible Employee, Consultant, or Non-Employee Director of any Affiliate if such
shares of Common Stock do not constitute “service recipient stock” for purposes of Section 409A with respect to such Eligible Employee, Consultant, or Non-Employee Director if such shares are
required to constitute “service recipient stock” for such Award to comply with, or be exempt from, Section 409A. 
 5.2
Incentive Stock Options. 
 Notwithstanding anything herein to the contrary, only Eligible Employees of the Company, its
Subsidiaries, and its Parent (if any) are eligible to be granted Incentive Stock Options under the Plan. Eligibility for the grant of an Incentive Stock Option and actual participation in the Plan shall be determined by the Committee. 

5.3 General Requirement. 

The grant of Awards to a prospective Eligible Employee or Consultant and the vesting and exercise of such Awards shall be conditioned
upon such Person actually becoming an Eligible Employee or Consultant; provided, however, that no Award may be granted to a prospective Eligible Employee or Consultant unless the Company determines that the Award will comply with
applicable laws, including the securities laws of all relevant jurisdictions (and, in the case of an Award to an Eligible Employee or Consultant pursuant to which Common Stock would be issued before such Person performing services for the Company,
the Company may require payment of not less than the par value of the Common Stock by cash or check to ensure proper issuance of the shares in compliance with applicable law). Awards may be awarded in consideration for past services actually
rendered to the Company or an Affiliate. 
 ARTICLE VI 

STOCK OPTIONS 
 6.1
Stock Options. 
 Each Stock Option shall be one of two types: (a) an Incentive Stock Option, or (b) a Non-Qualified Stock Option. The Committee shall have the authority to grant to any Eligible Employee Incentive Stock Options, Non-Qualified Stock Options, or both types of
Stock Options. The Committee shall have the authority to grant any Consultant or Non-Employee Director Non-Qualified Stock Options. To the extent that any Stock Option
does not qualify as an Incentive Stock Option (whether because of its provisions or the time or manner of its exercise or otherwise), such Stock Option or the portion thereof that does not qualify as an Incentive Stock Option shall constitute a
separate Non-Qualified Stock Option. 

  
 16 

 6.2 Incentive Stock Options. 

Notwithstanding anything herein to the contrary, no term of the Plan relating to Incentive Stock Options shall be interpreted, amended, or
altered, nor shall any discretion or authority granted under the Plan be so exercised, so as to disqualify the Plan under Section 422 of the Code, or, without the consent of the Participants affected, to disqualify any Incentive Stock Option
under Section 422 of the Code. 
 6.3 Terms of Stock Options. 

Stock Options granted under the Plan shall be subject to the following terms and conditions and shall be in such form and contain such
additional terms and conditions, not inconsistent with the terms of the Plan, as the Committee shall deem desirable: 
 (a) Exercise
Price. The exercise price per share of Common Stock subject to a Stock Option shall be determined by the Committee on or before the date of grant, provided that the per share exercise price of a Stock Option shall be not less than 100% (or, in
the case of an Incentive Stock Option granted to a Ten Percent Stockholder, 110%) of the Fair Market Value of the Common Stock on the date of grant. 

(b) Stock Option Term. The term of each Stock Option shall be fixed by the Committee, provided that no Stock Option shall be
exercisable more than ten years after the date such Stock Option is granted (or, in the case of an Incentive Stock Option granted to a Ten Percent Stockholder, five years). 

(c) Exercisability. 
 (i)
Stock Options shall be exercisable at such time or times and subject to such terms and conditions as shall be determined by the Committee in the applicable Award agreement; provided, however, that Stock Options shall be subject to a
minimum vesting schedule of at least one year from the date of grant, except that the Committee may provide (but shall have no obligation to do so) for accelerated vesting before the completion of such
one-year period upon a Change in Control or the Participant’s Disability or death. Notwithstanding the foregoing sentence, subject to the limitations set forth in Section 4, Awards with respect to up
to five percent (5%) of the total number of shares of Common Stock reserved for Awards under the Plan may be granted to any Participant without regard to any minimum vesting requirements. The Committee may waive any limitations on
exercisability at any time at or after grant in whole or in part, in its discretion. 
 (ii) Unless otherwise determined by the Committee in
the applicable Award agreement, (A) in the event the Participant engages in Detrimental Activity before any exercise of the Stock Option, all Stock Options held by the Participant shall thereupon terminate and expire, (B) as a condition of
the exercise of a Stock Option, the Participant shall be required to certify in a manner acceptable to the Company (or shall be deemed to have certified) that the Participant is in compliance with the terms and conditions of the Plan and that the
Participant has not engaged in, and does not intend to engage in, any Detrimental Activity, and (C) in the event the Participant engages in Detrimental Activity during the one-year period commencing on
the earlier of the date the Stock Option is exercised or the date of the Participant’s Termination, the Company shall be entitled to recover from the Participant at any time within one year after the date on which the Company becomes aware of
Participant’s engagement in such Detrimental Activity, and the Participant shall pay over to the Company, an amount equal to any gain realized (whether at the time of exercise or thereafter) as a result of the exercise. Unless otherwise
determined by the Committee in the applicable Award agreement, this Section 6.3(c)(ii) shall cease to apply upon a Change in Control. 

  
 17 

 (d) Method of Exercise. To the extent vested, a Stock Option may be exercised in whole or
in part at any time during the Option term, by giving written notice of exercise to the Committee (or its designee) specifying the number of shares of Common Stock to be purchased. Such notice shall be in a form acceptable to the Committee and shall
be accompanied by payment in full of the purchase price as follows: (i) in cash or by check, bank draft, or money order payable to the order of the Company; (ii) solely to the extent permitted by applicable law and authorized by the
Committee, if the Common Stock is traded on a national securities exchange or quoted on a national quotation system sponsored by the Financial Industry Regulatory Authority, through a procedure whereby the Participant delivers irrevocable
instructions to a broker reasonably acceptable to the Committee to deliver promptly to the Company an amount equal to the purchase price; or (iii) on such other terms and conditions as may be acceptable to the Committee (including the
relinquishment of Stock Options or by payment in full or in part in the form of Common Stock owned by the Participant (for which the Participant has good title, free and clear of any liens and encumbrances)). No shares of Common Stock shall be
issued until payment therefor, as provided herein, has been made or provided for. 
 (e)
Non-Transferability of Options. No Stock Option shall be Transferable by the Participant other than by will or by the laws of descent and distribution, and all Stock Options shall be exercisable, during
the Participant’s lifetime, only by the Participant. Notwithstanding the foregoing, the Committee may determine that a Non-Qualified Stock Option that otherwise is not Transferable pursuant to this
Section is Transferable to a Family Member in whole or in part, and in such circumstances, and under such conditions as specified by the Committee. A Non-Qualified Stock Option that is Transferred to a Family
Member pursuant to the preceding sentence (i) may not be Transferred subsequently other than by will or by the laws of descent and distribution, and (ii) remains subject to the terms of the Plan and the applicable Award agreement. Any
shares of Common Stock acquired upon the exercise of a Non-Qualified Stock Option by a permissible transferee of a Non-Qualified Stock Option or a permissible transferee
pursuant to a Transfer after the exercise of the Non-Qualified Stock Option shall be subject to the terms of this Plan and the applicable Award agreement. 

(f) Termination by Death or Disability. Unless otherwise determined by the Committee at grant (or, if no rights of the Participant (or,
in the case of his death, his estate) are reduced, thereafter), if a Participant’s Termination is by reason of death or Disability, all Stock Options that are held by such Participant that are vested and exercisable on the date of the
Participant’s Termination may be exercised by the Participant (or, in the case of death, by the legal representative of the Participant’s estate) at any time within a period of one year after the date of such Termination, but in no event
beyond the expiration of the stated term of such Stock Options. 
 (g) Involuntary Termination Without Cause. Unless otherwise
determined by the Committee at grant (or, if no rights of the Participant (or, in the case of his death, his estate) are reduced, thereafter), if a Participant’s Termination is by involuntary termination by the Company or an Affiliate without
Cause, all Stock Options that are held by such Participant that are vested and exercisable on the date of the Participant’s Termination may be exercised by the Participant at any time within a period of 90 days after the date of such
Termination, but in no event beyond the expiration of the stated term of such Stock Options. 

  
 18 

 (h) Voluntary Termination. Unless otherwise determined by the Committee at grant (or, if
no rights of the Participant (or, in the case of his death, his estate) are reduced, thereafter), if a Participant’s Termination is voluntary (other than a voluntary Termination described in subsection (i)(B) below), all Stock Options that
are held by such Participant that are vested and exercisable on the date of the Participant’s Termination may be exercised by the Participant at any time within a period of 30 days after the date of such Termination, but in no event beyond the
expiration of the stated term of such Stock Options. 
 (i) Termination for Cause. Unless otherwise determined by the Committee at
grant (or, if no rights of the Participant (or, in the case of his death, his estate) are reduced, thereafter), if a Participant’s Termination (A) is for Cause or (B) is a voluntary Termination after the occurrence of an event that
would be grounds for a Termination for Cause, all Stock Options, whether vested or not vested, that are held by such Participant shall terminate and expire on the date of such Termination. 

(j) Unvested Stock Options. Unless otherwise determined by the Committee, Stock Options that are not vested as of the date of a
Participant’s Termination for any reason shall terminate and expire on the date of such Termination. 
 (k) Incentive Stock Option
Limitations. To the extent that the aggregate Fair Market Value (determined as of the date of grant) with respect to which Incentive Stock Options are exercisable for the first time by an Eligible Employee during any calendar year under the Plan
and any other stock option plan of the Company, any Subsidiary, or any Parent exceeds $100,000, such Incentive Stock Options shall be treated as Non-Qualified Stock Options. In addition, if an Eligible
Employee does not remain employed by the Company, any Subsidiary, or any Parent at all times from the date an Incentive Stock Option is granted until three months before the date of exercise thereof (or such other period as required by applicable
law), such Stock Option shall be treated as a Non-Qualified Stock Option. Should any provision of the Plan not be necessary in order for the Stock Options to qualify as Incentive Stock Options, or should any
additional provisions be required, the Committee may amend the Plan accordingly, without the necessity of obtaining the approval of the stockholders of the Company. 

(l) Form, Modification, Extension, and Renewal of Stock Options. Stock Options may be evidenced by such form of agreement as is approved
by the Committee. The Committee may (i) modify, extend, or renew outstanding Stock Options (provided that (A) the rights of a Participant are not reduced without his consent, and (B) such action does not subject the Stock
Options to Section 409A or otherwise extend the Stock Options beyond their stated term), and (ii) accept the surrender of outstanding Stock Options and authorize the granting of new Stock Options in substitution therefor. Notwithstanding
anything herein to the contrary, an outstanding Option may not be modified to reduce the exercise price thereof nor may a new Option at a lower exercise price be substituted for a surrendered Option (other than adjustments or substitutions in
accordance with Section 4.2), unless such action is approved by the stockholders of the Company. 
 (m) No Reload Options.
Options shall not provide for the grant of the same number of Options as the number of shares used to pay for the exercise price of Options or shares used to pay withholding taxes (i.e., “reloads”). 

  
 19 

 ARTICLE VII 

RESTRICTED STOCK 
 7.1
Awards of Restricted Stock. 
 The Committee shall determine the Participants to whom, and the time or times at which, grants of
Restricted Stock shall be made, the number of shares to be awarded, the purchase price (if any) to be paid by the Participant (subject to Section 7.2), the time or times at which such Awards may be subject to forfeiture or to restrictions on
transfer, and all other terms and conditions of the Awards. 
 Unless otherwise determined by the Committee in the applicable Award
agreement, (A) in the event the Participant engages in Detrimental Activity before any vesting of Restricted Stock, all unvested Restricted Stock shall be immediately forfeited, and (B) in the event the Participant engages in Detrimental
Activity during the one-year period after any vesting of such Restricted Stock, the Committee shall be entitled to recover from the Participant (at any time within one year after such engagement in Detrimental Activity) an amount equal to the Fair
Market Value as of the vesting date(s) of any Restricted Stock that had vested in the period referred to above. Unless otherwise determined by the Committee in the applicable Award agreement, this paragraph shall cease to apply upon a Change in
Control. 
 The Committee may condition the grant or vesting of Restricted Stock upon the attainment of specified performance goals
(including goals based on the Performance Criteria) or such other factors as the Committee may determine. 
 7.2 Awards and Certificates.

 The Committee may require, as a condition to the effectiveness of an Award of Restricted Stock, that the Participant execute and
deliver to the Company an Award agreement or other documentation and comply with the terms of such Award agreement or other documentation. Further, Restricted Stock shall be subject to the following conditions: 

(a) Purchase Price. The purchase price of Restricted Stock, if any, shall be fixed by the Committee. In accordance with
Section 4.3, the purchase price for shares of Restricted Stock may be zero to the extent permitted by applicable law, and, to the extent not so permitted, such purchase price may not be less than the minimum purchase price required under
applicable law. 
 (b) Legend. Each Participant receiving Restricted Stock shall be issued a stock certificate in respect of such
shares of Restricted Stock, unless the Committee elects to use another system, such as book entries by the transfer agent, as evidencing ownership of shares of Restricted Stock. Such certificate shall be registered in the name of such Participant,
and shall, in addition to such legends required by applicable securities laws, if any, bear an appropriate legend referring to the terms, conditions, and restrictions applicable to such Award, substantially in the following form: 

“The anticipation, alienation, attachment, sale, transfer, assignment, pledge, encumbrance, or charge of the shares of
stock represented hereby are subject to the terms and conditions (including forfeiture) of the Solid Biosciences Inc. (the “Company”) 2018 Omnibus Incentive Plan (as amended from time to time, the
“Plan”), and an Award Agreement entered into between the registered owner and the Company dated                 . Copies of such Plan and
Award Agreement are on file at the principal office of the Company.” 

  
 20 

 (c) Custody. If stock certificates are issued in respect of shares of Restricted Stock,
the Committee may require that any stock certificates evidencing such shares be held in custody by the Company until the restrictions thereon shall have lapsed, and that, as a condition of any grant of Restricted Stock, the Participant shall have
delivered a duly signed stock power or other instruments of assignment (including a power of attorney), each endorsed in blank with a guarantee of signature if deemed necessary or appropriate by the Company, which would permit transfer to the
Company of all or a portion of the shares subject to the Award of Restricted Stock in the event that such Award is forfeited in whole or part. 

7.3 Restrictions and Conditions. 

Restricted Stock shall be subject to the following restrictions and conditions: 

(a) Restriction Period. 

(i) The Participant shall not be permitted to Transfer shares of Restricted Stock, and the Restricted Stock shall be subject to a risk of
forfeiture (collectively, “restrictions”) during the period or periods set by the Committee (the “Restriction Periods”), as set forth in the Restricted Stock Award agreement. The Committee may provide for the lapse
of the restrictions in whole or in part (including in installments) based on service, attainment of performance goals, or such other factors or criteria as the Committee may determine, and may waive all or any part of the restrictions at any time
subject to Section 7.3(a)(iii). 
 (ii) If the grant of Restricted Stock or the lapse of restrictions is based on the attainment of
performance goals, such performance goals shall be established by the Committee in writing on or before the date the grant of Restricted Stock is made and while the outcome of the performance goals is substantially uncertain and, following the
Transition Period, that is permitted under Section 162(m) with regard to an Award of Restricted Stock that is intended to comply with Section 162(m). Such performance goals may incorporate provisions for disregarding (or adjusting for)
changes in accounting methods, corporate transactions (including dispositions and acquisitions), and other similar events or circumstances. Following the Transition Period, with regard to an Award of Restricted Stock that is intended to comply with
Section 162(m), (A) to the extent that any such provision set forth in the prior sentence would create impermissible discretion under Section 162(m) or otherwise violate Section 162(m), such provision shall be of no force or
effect, and (B) the applicable performance goals shall be based on one or more of the Performance Criteria. For the avoidance of doubt, during the Transition Period, the Committee may establish such performance goals as it determines. 

(iii) Notwithstanding anything herein to the contrary, Awards of Restricted Stock shall be subject to a minimum vesting schedule of at least
one year from the date of grant, except that the Committee may provide (but shall have no obligation to do so) for accelerated vesting before the completion of such one-year period upon a Change in Control or
the Participant’s Disability or death. Notwithstanding the foregoing sentence, subject to the limitations set forth in Section 4, Awards with respect to up to five percent (5%) of the total number of shares of Common Stock reserved
for Awards under the Plan may be granted to any Participant without regard to any minimum vesting requirements. 

  
 21 

 (b) Rights as a Stockholder. Except as otherwise determined by the Committee, the
Participant shall have all the rights of a holder of shares of Common Stock of the Company with respect to Restricted Stock, subject to the following provisions of this Section 7.3(b). Except as otherwise determined by the Committee,
(i) the Participant shall have no right to tender shares of Restricted Stock, (ii) Dividends on shares of Restricted Stock shall be withheld, in each case, while the Restricted Stock is subject to restrictions, and (iii) in no event
shall Dividends payable thereunder be paid unless and until the shares of Restricted Stock to which they relate no longer are subject to a risk of forfeiture. Dividends that are not paid currently shall be credited to bookkeeping accounts on the
Company’s records for purposes of the Plan and, except as otherwise determined by the Committee, shall not accrue interest. Such Dividends shall be paid to the Participant in the same form as paid on the Common Stock upon the lapse of the
restrictions. The obligation of the Company to pay any Dividends hereunder upon lapse of the applicable restrictions shall be a general, unsecured obligation of the Company payable solely from the general assets of the Company. In no event shall the
Company be required, or have any obligation, to set aside, or hold in escrow or trust, any funds for the purpose of paying such Dividends. 

(c) Termination. Upon a Participant’s Termination for any reason during the Restriction Period, all Restricted Stock still subject
to restriction will vest or be forfeited in accordance with the terms and conditions established by the Committee at grant, or, if no rights of a Participant are reduced, thereafter. 

(d) Lapse of Restrictions. If and when the Restriction Period expires without a prior forfeiture of the Restricted Stock, the
certificates for such shares shall be delivered to the Participant, and any and all unpaid distributions or Dividends payable thereunder shall be paid. All legends shall be removed from said certificates at the time of delivery to the Participant,
except as otherwise required by applicable law or other limitations imposed by the Committee. 
 ARTICLE VIII 

OTHER STOCK-BASED AWARDS 

8.1 Other Awards. 

The Committee is authorized to grant Other Stock-Based Awards that are payable in, valued in whole or
in part by reference to, or otherwise based on or related to shares of Common Stock, including but not limited to, shares of Common Stock awarded purely as a bonus and not subject to any restrictions or conditions, shares of Common Stock in payment
of the amounts due under an incentive or performance plan sponsored or maintained by the Company or an Affiliate, stock appreciation rights, stock equivalent units, restricted stock units, Performance Shares, Performance Units, and Awards valued by
reference to book value of shares of Common Stock. 
 The Committee shall have authority to determine the Participants to whom, and the time
or times at which, Other Stock-Based Awards shall be made, the number of shares of Common Stock to be awarded pursuant to such Awards, and all other terms and conditions of the Awards. 

  
 22 

 The Committee may condition the grant or vesting of Other
Stock-Based Awards upon the attainment of performance goals (including, performance goals based on the Performance Criteria) or such other factors as the Committee may determine. If the grant or vesting of an
Other Stock-Based Award is based on the attainment of performance goals, such performance goals shall be established by the Committee in writing on or before the date the grant of Other Stock-Based Award is made and while the outcome of the performance goals is substantially uncertain and, following the Transition Period, that is permitted under Section 162(m) with regard to an Other Stock-Based Award that is intended to comply with Section 162(m). Such performance goals may incorporate provisions for disregarding (or adjusting for) changes in accounting methods, corporate transactions
(including dispositions and acquisitions), and other similar events or circumstances. Following the Transition Period, with regard to an Other Stock-Based Award that is intended to comply with
Section 162(m), (a) to the extent any such provision set forth in the prior sentence would create impermissible discretion under Section 162(m) or otherwise violate Section 162(m), such provision shall be of no force or effect,
and (b) the applicable performance goals shall be based on one or more of the Performance Criteria. For the avoidance of doubt, during the Transition Period, the Committee may establish such performance goals as it determines. 

8.2 Terms and Conditions. 

Other Stock-Based Awards made pursuant to this Article VIII shall be subject to the following
terms and conditions: 
 (a) Non-Transferability. The Participant may not Transfer Other Stock-Based Awards or the Common Stock underlying such Awards before the date on which the underlying Common Stock is issued, or, if later, the date on which any restriction, performance, or deferral period
applicable to such Common Stock lapses. 
 (b) Dividends. The Committee shall determine to what extent, and under what conditions, the
Participant shall have the right to receive Dividends with respect to shares of Common Stock covered by Other Stock-Based Awards. Except as otherwise determined by the Committee, Dividends with respect to
unvested Other Stock-Based Awards shall be withheld until such Other Stock-Based Awards vest. Dividends that are not paid currently shall be credited to bookkeeping
accounts on the Company’s records for purposes of the Plan and, except as otherwise determined by the Committee, shall not accrue interest. Such Dividends shall be paid to the Participant in the same form as paid on the Common Stock or such
other form as is determined by the Committee upon the lapse of the restrictions. The obligation of the Company to pay any Dividends hereunder upon lapse of the applicable restrictions shall be a general, unsecured obligation of the Company payable
solely from the general assets of the Company. In no event shall the Company be required, or have any obligation, to set aside, or hold in escrow or trust, any funds for the purpose of paying such Dividends. 

(c) Vesting. Other Stock Based Awards and any underlying Common Stock shall vest or be forfeited to the extent set forth in the
applicable Award agreement or as otherwise determined by the Committee. At the expiration of any applicable Performance Period, the Committee shall determine the extent to which the relevant performance goals are achieved and the portion of each
Other Stock-Based Award that has been earned. The Committee may, at or after grant, accelerate the vesting of all or any part of any Other Stock-Based Award.
Notwithstanding anything herein to the contrary, Other Stock-Based Awards shall be subject to a minimum vesting schedule of at least one year from the date of grant, except that the Committee may provide (but
shall have no obligation to do so) for 

  
 23 

 
accelerated vesting before the completion of such one-year period upon a Change in Control or the Participant’s Disability or death. Notwithstanding
the foregoing sentence, subject to the limitations set forth in Section 4, Awards with respect to up to five percent (5%) of the total number of shares of Common Stock reserved for Awards under the Plan may be granted to any Participant
without regard to any minimum vesting requirements. 
 (d) Payment. Following the Committee’s determination in accordance with
subsection (c) above, shares of Common Stock or, as determined by the Committee, the cash equivalent of such shares, shall be delivered to the Participant, or his legal representative, in an amount equal to such individual’s earned Other Stock-Based Award. Notwithstanding the foregoing, the Committee may exercise negative discretion by providing in an Other Stock-Based Award the discretion to pay an amount
less than otherwise would be provided under the applicable level of attainment of the performance goals or subject the payment of all or part of any Other Stock-Based Award to additional vesting, forfeiture,
and deferral conditions as it deems appropriate. 
 (e) Detrimental Activity. Unless otherwise determined by the Committee in the
applicable Award agreement, (A) in the event the Participant engages in Detrimental Activity before any vesting of such Other Stock-Based Award, all unvested Other
Stock-Based Award shall be immediately forfeited, and (B) in the event the Participant engages in Detrimental Activity during the one-year period after any vesting of such Other Stock-Based Award, the Committee shall be entitled to recover from the Participant (at any time within the one-year period after such engagement in Detrimental Activity) an
amount equal to any gain the Participant realized from any Other Stock-Based Award that had vested in the period referred to above. Unless otherwise determined by the Committee in the applicable Award
agreement, this Section 8.2(e) shall cease to apply upon a Change in Control. 
 (f) Price. Common Stock issued on a bonus basis
under this Article VIII may be issued for no cash consideration; Common Stock purchased pursuant to a purchase right awarded under this Article VIII shall be priced as determined by the Committee. 

(g) Termination. Upon a Participant’s Termination for any reason during the Performance Period, the Other Stock-Based Awards will vest or be forfeited in accordance with the terms and conditions established by the Committee at grant or, if no rights of the Participant are reduced, thereafter. 

ARTICLE IX 
 PERFORMANCE-BASED CASH AWARDS 
 9.1 Performance-Based
Cash Awards. 
 The Committee shall have authority to determine the Eligible Employees and Consultants to whom, and the time or
times at which, Performance-Based Cash Awards shall be made, the dollar amount to be awarded pursuant to such Performance-Based Cash Award, and all other conditions for
the payment of the Performance-Based Cash Award. 
 Except as otherwise provided herein, the
Committee shall condition the right to payment of any Performance-Based Cash Award upon the attainment of specified performance goals (including performance goals based on the Performance Criteria) established
pursuant to Section 9.2(c) and such other factors as the Committee may determine, including to comply with the requirements of Section 162(m). The Committee may establish different performance goals for different Participants. 

  
 24 

 Subject to Section 9.2(c), for any Participant the Committee may specify a targeted Performance-Based Cash Award for a Performance Period (each an “Individual Target Award”). An Individual Target Award may be expressed, at the Committee’s discretion, as a fixed dollar
amount, a percentage of the Participant’s base pay, as a percentage of a bonus pool funded by a formula based on achievement of performance goals, or an amount determined pursuant to an objective formula or standard. The Committee’s
establishment of an Individual Target Award for a Participant for a Performance Period shall not imply or require that the same level or any Individual Target Award be established for the Participant for any subsequent Performance Period or for any
other Participant for that Performance Period or any subsequent Performance Period. At the time the performance goals are established (as provided in Section 9.2(c)), the Committee shall prescribe a formula to determine the maximum and minimum
percentages (which may be greater or less than 100% of an Individual Target Award) that may be earned or payable based upon the degree of attainment of the performance goals during the Performance Period. Notwithstanding anything herein to the
contrary, the Committee may exercise negative discretion by providing in an Individual Target Award the discretion to pay a Participant an amount that is less than the Participant’s Individual Target Award (or attained percentages thereof)
regardless of the degree of attainment of the performance goals; provided that, except as otherwise specified by the Committee with respect to an Individual Target Award, no discretion to reduce a
Performance-Based Cash Award earned based on achievement of the applicable performance goals shall be permitted for any Performance Period in which a Change in Control occurs, or during such Performance Period
with regard to the prior Performance Periods if the Performance-Based Cash Awards for the prior Performance Periods have not been paid by the time of the Change in Control, with regard to individuals who were
Participants at the time of the Change in Control. 
 9.2 Terms and Conditions. 

Performance-Based Cash Awards shall be subject to the following terms and conditions: 

(a) Committee Certification. At the expiration of the applicable Performance Period, the Committee shall determine and certify in
writing the extent to which the performance goals established pursuant to Section 9.2(c) are achieved and, if applicable, the percentage of the Performance-Based Cash Award that has been vested and
earned. 
 (b) Waiver of Limitation. In the event of the Participant’s Disability or death, or in cases of special circumstances
(to the extent permitted under Section 162(m) with regard to a Performance-Based Cash Award that is intended to comply with Section 162(m)), the Committee may waive in whole or in part any or all of
the limitations imposed thereunder with respect to any or all of a Performance-Based Cash Award. 

(c) Performance Goals, Formulae, or Standards. The performance goals for the earning of
Performance-Based Cash Awards shall be established by the Committee in writing on or before the date the grant of Performance-Based Cash Award is made and while the
outcome of the performance goals is substantially uncertain and, following the Transition Period, that is permitted under Section 162(m) with regard to a Performance-Based Cash Award that is intended to
comply with Section 162(m). Such performance goals may incorporate provisions 

  
 25 

 
for disregarding (or adjusting for) changes in accounting methods, corporate transactions (including dispositions and acquisitions), and other similar events or circumstances. Following the
Transition Period, with regard to a Performance-Based Cash Award that is intended to comply with Section 162(m), (i) to the extent any such provision set forth in the prior sentence would create
impermissible discretion under Section 162(m) or otherwise violate Section 162(m), such provision shall be of no force or effect and (ii) the applicable performance goals shall be based on one or more of the Performance Criteria. For
the avoidance of doubt, during the Transition Period, the Committee may establish such performance goals as it determines. 
 (d)
Payment. Following the Committee’s determination and certification in accordance with subsection (a) above, the earned Performance-Based Cash Award amount shall be paid to the Participant
or his legal representative, in accordance with the terms and conditions set forth in the Performance-Based Cash Award agreement, but in no event, except as provided in the next sentence, shall such amount be
paid later than the later of: (i) March 15 of the year following the year in which the applicable Performance Period ends (or, if later, the year in which the Award is earned); or (ii) two and
one-half months after the expiration of the fiscal year of the Company in which the applicable Performance Period ends. Notwithstanding the foregoing, the Committee may place such conditions on the payment of
all or any portion of any Performance-Based Cash Award as the Committee may determine and before the beginning of a Performance Period, the Committee may (A) provide that the payment of all or any portion
of any Performance-Based Cash Award shall be deferred, and (B) permit a Participant to elect to defer receipt of all or a portion of any Performance-Based Cash
Award. Any Performance-Based Cash Award deferred by a Participant in accordance with the terms and conditions established by the Committee shall not increase (between the date on which the Performance-Based Cash Award is credited to any deferred compensation program applicable to such Participant and the payment date) by an amount that would result in such deferral being deemed as an “increase in
the amount of compensation” under Section 162(m). To the extent applicable, any deferral under this Section 9.2(d) shall be made in a manner intended to comply with or be exempt from the applicable requirements of Section 409A.
Notwithstanding the foregoing, the Committee may exercise negative discretion by providing in a Performance-Based Cash Award the discretion to pay an amount less than otherwise would be provided under the
applicable level of attainment of the performance goals. 
 (e) Termination. Unless otherwise determined by the Committee at the time
of grant (or, if no rights of the Participant (or, in the case of his death, his estate) are reduced, thereafter), no Performance-Based Cash Award or pro rata portion thereof shall be payable to any
Participant who incurs a Termination before the date such Performance-Based Cash Award is paid and the Performance-Based Cash Awards only shall be deemed to be earned
when actually paid. 

  
 26 

 ARTICLE X 

CHANGE IN CONTROL PROVISIONS 

10.1 In the event of a Change in Control of the Company, except as otherwise provided by the Committee in an Award agreement or
otherwise in writing, a Participant’s unvested Award shall not vest and a Participant’s Award shall be treated in accordance with one of the following methods as determined by the Committee: 

(a) Awards, whether or not then vested, may be continued, assumed, have new rights substituted therefor, or be treated in accordance with
Section 4.2(d), and Restricted Stock or other Awards may, where appropriate in the discretion of the Committee, receive the same distribution as other Common Stock on such terms as determined by the Committee; provided that, the
Committee may decide to award additional Restricted Stock or any other Award in lieu of any cash distribution. Notwithstanding anything herein to the contrary, any assumption or substitution of Incentive Stock Options shall be structured in a manner
intended to comply with the requirements of Treasury Regulation § 1.424-1 (and any amendments thereto). 

(b) Awards may be canceled in exchange for an amount of cash equal to the Change in Control Price (as defined below) per share of Common Stock
covered by such Awards), less, in the case of an Appreciation Award, the exercise price per share of Common Stock covered by such Award. The “Change in Control Price” means the price per share of Common Stock paid in the
Change in Control transaction. 
 (c) Appreciation Awards may be cancelled without payment, if the Change in Control Price is less than the
exercise price per share of such Appreciation Awards. 
 Notwithstanding anything herein to the contrary, the Committee may provide for accelerated vesting
or lapse of restrictions, of an Award at any time. 

  
 27 

 ARTICLE XI 

TERMINATION OR AMENDMENT OF PLAN 

Notwithstanding anything herein to the contrary, the Board, or the Committee (to the extent permitted by law), may at any time, and from time
to time, amend, in whole or in part, any or all of the provisions of the Plan (including any amendment deemed necessary or advisable to ensure that the Company may comply with any regulatory requirement referred to in Article XIII or
Section 409A), or suspend or terminate it entirely, retroactively or otherwise; provided, however, that, unless otherwise required by law or specifically provided herein, the rights of a Participant with respect to Awards granted
before such amendment, suspension, or termination may not be reduced in any material respect without the consent of such Participant and, provided further, without the approval of the holders of the Company’s Common Stock entitled to
vote in accordance with applicable law, no amendment may be made that would (a) increase the aggregate number of shares of Common Stock that may be issued under the Plan (except by operation of Section 4.2); (b) increase the maximum
individual Participant limits under Section 4.1(b) (except by operation of Section 4.2); (c) change the classification of individuals eligible to receive Awards under the Plan; (d) extend the maximum term of Options;
(e) alter the Performance Criteria; (f) other than adjustments or substitutions in accordance with Section 4.2, amend the terms of outstanding Awards to reduce the exercise price of outstanding Stock Options or Appreciation Awards, or
cancel outstanding Stock Options or Appreciation Awards (where, before the reduction or cancellation, the exercise price exceeds the Fair Market Value on the date of cancellation) in exchange for cash, other Awards, or Stock Options or Appreciation
Awards with an exercise price that is less than the exercise price of the original Stock Options or Appreciation Awards; or (g) otherwise require stockholder approval in order for the Plan or any of the Awards issued hereunder to continue to
comply with applicable law (including Sections 162(m) and 422 of the Code) or the rules of any applicable securities exchange or system on which the Company’s securities are listed or traded at the request of the Company. 

The Committee may amend the terms of any Award theretofore granted, prospectively or retroactively; provided that no such
amendment reduces in any material respect the rights of any Participant without the Participant’s consent. Actions taken by the Committee in accordance with Article IV shall not be deemed to reduce the rights of any Participant.

 Notwithstanding anything herein to the contrary, the Board or the Committee may amend the Plan or any Award at any time without a
Participant’s consent to comply with Section 409A or any other applicable law. 
 ARTICLE XII  

UNFUNDED PLAN 
 The Plan
is intended to constitute an “unfunded” plan for incentive and deferred compensation. With respect to any payments as to which a Participant has a fixed and vested interest but which are not yet made to a Participant by the Company,
nothing contained herein shall give any such Participant any rights that are greater than those of a general unsecured creditor of the Company. 

  
 28 

 ARTICLE XIII 

GENERAL PROVISIONS 

13.1 Legend. 
 The
Committee may require each person receiving shares of Common Stock pursuant to an Award to represent to and agree with the Company in writing that the Participant is acquiring the shares without a view to distribution thereof and such other
securities law-related representations as the Committee shall request. In addition to any legend required by the Plan, the certificates or book entry accounts for such shares may include any legend that the Committee deems appropriate to reflect any
restrictions on Transfer. 
 All certificates or book entry accounts for shares of Common Stock delivered under the Plan shall be subject to
such stop transfer orders and other restrictions as the Committee may deem advisable under the rules, regulations, and other requirements of the Securities and Exchange Commission, any stock exchange upon which the Common Stock is then listed or any
national automated quotation system on which the Common Stock is then quoted, any applicable Federal or state securities law, and any applicable corporate law, and the Committee may cause a legend or legends to be put on any such certificates to
make appropriate reference to such restrictions. If necessary or advisable to prevent a violation of applicable securities laws or to avoid the imposition of public company reporting requirements, then, notwithstanding anything herein to the
contrary, any stock-settled Awards shall be paid in cash in an amount equal to the Fair Market Value on the date of settlement of such Awards. 

13.2 Other Plans. 

Nothing contained in the Plan shall prevent the Board from adopting other or additional compensation arrangements, subject to stockholder
approval if such approval is required; and such arrangements may be either generally applicable or applicable only in specific cases. 

13.3 No Right to Employment, Consultancy, or Directorship. 

Neither the Plan nor the grant of any Award hereunder shall give any Participant or other person any right to employment, consultancy, or
directorship by the Company or any Affiliate, or limit in any way the right of the Company or any Affiliate by which an employee is employed or a Consultant or Non-Employee Director is retained to terminate
their employment, consultancy, or directorship at any time. 
 13.4 Withholding of Taxes. 

The Company or any Affiliate shall have the right to deduct from any payment to be made pursuant to the Plan, or to otherwise require, before
the issuance or delivery of any shares of Common Stock or the payment of any cash, payment by the Participant of any Federal, foreign, state, or local taxes required by law to be withheld. Upon the vesting of Restricted Stock (or other Award that is
taxable upon vesting), or upon making an election under Section 83(b) of the Code, a Participant shall pay all required withholding to the Company or any Affiliate. Any statutorily required withholding obligation with regard to any Participant
may be satisfied, subject to the consent of the Committee, by reducing the number of shares of Common Stock otherwise deliverable or by delivering shares of Common Stock already owned. Any fraction of a share of Common Stock required to satisfy such
tax obligations shall be disregarded, and the amount due shall be paid instead in cash by the Participant. 

  
 29 

 13.5 No Assignment of Benefits. 

No Award or other benefit payable under the Plan shall, except as otherwise specifically provided in the Plan or permitted by the Committee,
be Transferable in any manner, and any attempt to Transfer any such benefit shall be null and void, and any such benefit shall not in any manner be liable for or subject to the debts, contracts, liabilities, engagements, or torts of any person who
shall be entitled to such benefit, nor shall it be subject to attachment or legal process for or against such person. 
 13.6 Listing
and Other Conditions. 
 (a) Unless otherwise determined by the Committee, as long as the Common Stock is listed on a national
securities exchange or system sponsored by a national securities association, the issuance of shares of Common Stock pursuant to an Award shall be conditioned upon such shares being listed on such exchange or system. The Company shall have no
obligation to issue such shares unless and until such shares are so listed, and the right to exercise any Stock Option or other Exercisable Award with respect to such shares shall be suspended until such listing has been effected. 

(b) If at any time counsel to the Company shall be of the opinion that any offer or sale of Common Stock pursuant to an Award is or may be
unlawful or prohibited, or will or may result in the imposition of excise taxes on the Company, under the statutes, rules, or regulations of any applicable jurisdiction or under the rules of the national securities exchange on which the Common Stock
then is listed, the Company shall have no obligation to make such offer or sale, or to make any application or to effect or to maintain any qualification or registration under the Securities Act or otherwise, with respect to the Common Stock or
Awards, and the right to exercise any Stock Option or other Exercisable Award shall be suspended until, in the opinion of said counsel, such offer or sale shall be lawful, permitted, or will not result in the imposition of excise taxes on the
Company. 
 (c) Upon termination of any period of suspension under this Section 13.6, any Award affected by such suspension that shall
not then have expired or terminated shall be reinstated as to all shares available before such suspension and as to shares that would otherwise have become available during the period of such suspension, but no such suspension shall extend the term
of any Award. 
 (d) A Participant shall be required to supply the Company with certificates, representations, and information that the
Company requests and otherwise cooperate with the Company in obtaining any listing, registration, qualification, exemption, consent, or approval the Company deems necessary or appropriate. 

13.7 Governing Law. 

The Plan and matters arising under or related to it shall be governed by and construed in accordance with the internal laws of the State of
Delaware without giving effect to its principles of conflicts of laws. 
 13.8 Construction. 

Wherever any words are used in the Plan in the masculine, feminine, or neutral gender they shall be construed as though they were also used in
the masculine, feminine, or neutral gender (as the case may be) in all cases where they would so apply. As used herein, (a) “or” shall mean “and/or,” and (b) “including” or “include” shall mean
“including, without limitation.” Any reference herein to an agreement in writing shall be deemed to include an electronic writing to the extent permitted by applicable law. 

  
 30 

 13.9 No Acquired Rights. 

By participating in the Plan, each Participant is deemed to acknowledge and accept that the Committee has the sole discretion to amend or
terminate the Plan, to the extent permitted hereunder, at any time and that the opportunity given to a Participant to participate in the Plan is at the sole discretion of the Committee and does not obligate the Company or any Affiliate to offer such
participation in the future (whether on the same or different terms). By participating in the Plan, each Participant is deemed further to acknowledge and accept that (i) such Participant’s participation in the Plan is not to be considered
part of any normal or expected compensation, (ii) the value of Awards granted to a Participant shall not be used for purposes of determining any benefits or compensation payable to the Participant or the Participant’s beneficiaries or
estate under any benefit arrangement of the Company or its Affiliates, and (iii) the termination of the Participant’s employment with the Company or an Affiliate under any circumstance whatsoever will not give the Participant any claim or
right of action against the Company or any of its Affiliates in respect of any lost rights under the Plan that may arise as a result of such termination of employment. 

13.10 Data Protection. 

By participating in the Plan, each Participant shall consent to the holding and processing of personal information provided by such
Participant to the Company, any Affiliate, trustee, or third-party service provider for all purposes relating to the operation of the Plan. These include: (i) administering and maintaining Participant
records; (ii) providing information to the Company, Affiliates, trustees of any employee benefit trust, registrars, brokers, or third-party administrators of the Plan; (iii) providing information to
future purchasers or merger partners of the Company or any Affiliate or the business in which the Participant works; and (iv) transferring personal information about the Participant to any country or territory that may not provide the same
protection for the information as the Participant’s home country. Such personal information may include the Participant’s name, home address, and telephone number; date of birth; social security or insurance number; other identification
number; salary; nationality; job title; any shares or directorships held in the Company or an Affiliate; and details of all Awards or other entitlement to shares awarded, canceled, exercised, vested, unvested, or outstanding in a Participant’s
favor. 
 13.11 Costs. 

The Company shall bear all expenses associated with administering the Plan, including expenses of issuing Common Stock pursuant to any Awards.

 13.12 No Right to Same Benefits. 

The provisions of Awards need not be the same with respect to each Participant, and each Award to an individual Participant need not be the
same. 
 13.13 Death or Disability. 

The Committee may require the transferee of a Participant to supply it with written notice of the Participant’s death or Disability and
to supply it with a copy of the will (in the case of the Participant’s death) or such other evidence as the Committee deems necessary or advisable to establish the validity of the transfer of an Award. The Committee also may require that the
transferee agree to be bound by all of the terms and conditions of the Plan. 

  
 31 

 13.14 Section 16(b) of the Exchange Act. 

All elections and transactions under the Plan by persons subject to Section 16 of the Exchange Act involving shares of Common Stock are
intended to comply with any applicable exemptive condition under Rule 16b-3. The Committee may establish and adopt written administrative guidelines, designed to facilitate compliance with
Section 16(b) of the Exchange Act, as it may deem necessary or advisable for the administration and operation of the Plan and the transaction of business thereunder. 

13.15 Section 409A. 

Although the Company does not guarantee to a Participant the particular tax treatment of any Award, all Awards are intended to comply
with, or be exempt from, the requirements of Section 409A, and the Plan and any Award agreement shall be limited, construed, and interpreted in accordance with such intent. To the extent that any Award constitutes
“non-qualified deferred compensation” pursuant to Section 409A (a “Section 409A Covered Award”), it is intended to be paid in a manner that will comply with
Section 409A. In no event shall the Company be liable for any additional tax, interest, or penalties that may be imposed on a Participant by Section 409A or for any damages or other penalties or awards for failing to comply with
Section 409A. Notwithstanding anything herein or in an Award to the contrary, the following provisions shall apply to Section 409A Covered Awards: 

(a) A termination of employment shall not be deemed to have occurred for purposes of any provision of a Section 409A Covered Award
providing for payment upon or following a termination of the Participant’s employment unless such termination is also a “separation from service” within the meaning of Section 409A and, for purposes of any such provision of a
Section 409A Covered Award, references to a “termination,” “termination of employment,” or like terms shall mean separation from service within the meaning of Section 409A. Notwithstanding anything herein or in an Award
to the contrary, if the Participant is deemed on the date of the Participant’s Termination to be a “specified employee” within the meaning of that term under Section 409A(a)(2)(B) of the Code and using the identification
methodology selected by the Company from time to time, or if none, the default methodology set forth in Section 409A, then with regard to any such payment under a Section 409A Covered Award, to the extent required to be delayed in
compliance with Section 409A(a)(2)(B) of the Code, such payment shall not be made before the earlier of (i) the expiration of the six-month period measured from the date of the Participant’s
separation from service, and (ii) the date of the Participant’s death. All payments delayed pursuant to this Section 13.15(a) shall be paid to the Participant on the first day of the seventh month following the date of the
Participant’s separation from service or, if earlier, on the date of the Participant’s death. 
 (b) With respect to any payment
pursuant to a Section 409A Covered Award that is triggered upon a Change in Control, unless otherwise provided by the Committee in the applicable Award agreement, the settlement of such Award shall not occur until the earliest of (i) the
Change in Control if such Change in Control constitutes a “change in the ownership of the corporation,” a “change in effective control of the corporation,” or a “change in the ownership of a substantial portion of the assets
of the corporation,” within the meaning of 

  
 32 

 
Section 409A(a)(2)(A)(v) of the Code, (ii) the date such Award otherwise would be settled pursuant to the terms of the applicable Award agreement, and (iii) the Participant’s
“separation from service” within the meaning of Section 409A, subject to Section 13.15(a). 
 (c) For purposes of
Section 409A, a Participant’s right to receive any installment payments under the Plan or pursuant to an Award shall be treated as a right to receive a series of separate and distinct payments. 

(d) Whenever a payment under the Plan or pursuant to an Award specifies a payment period with reference to a number of days (e.g.,
“payment shall be made within 30 days following the date of termination”), the actual date of payment within the specified period shall be within the sole discretion of the Company. 

13.16 Successor and Assigns. 

The Plan shall be binding on all successors and permitted assigns of a Participant, including the estate of such Participant and the executor,
administrator, or trustee of such estate. 
 13.17 Severability of Provisions. 

If any provision of the Plan shall be held invalid or unenforceable, such invalidity or unenforceability shall not affect any other provisions
hereof, and the Plan shall be construed and enforced as if such provisions had not been included. 
 13.18 Participants Subject to
Taxation Outside the U.S.; No Tax Equalization. 
 With respect to a Participant who is subject to taxation in a country other than
the United States, the Committee may grant Awards to such Participant on such terms and conditions as the Committee deems appropriate to comply with the laws of the applicable country, and the Committee may create such procedures, addenda, and
subplans and make such modifications as may, in the Committee’s discretion, be necessary or desirable to comply with such laws. Neither the Company nor any Affiliate shall have any responsibility to such Participant with respect to any taxes
owed or owing in or to any jurisdiction that such Participant incurs as a result of receiving an Award and becoming a Participant in the Plan, nor shall the Company or any Affiliate provide any tax equalization payment to any Participant in respect
of taxes owed or owing in or to any jurisdiction by a Participant. 
 13.19 Payments to Minors, Etc. 

Any benefit payable to or for the benefit of a minor, an incompetent person, or other person incapable of receipt thereof shall be deemed paid
when paid to such person’s guardian or to the party providing or reasonably appearing to provide for the care of such person, and such payment shall fully discharge the Committee, the Board, the Company, its Affiliates, and their employees,
agents, and representatives with respect thereto. 
 13.20 Headings and Captions. 

The headings and captions herein are provided for reference and convenience only, shall not be considered part of the Plan, and shall not be
employed in the construction of the Plan. 

  
 33 

 13.21 Recoupment. 

In addition to any recoupment provisions set forth herein relating to Detrimental Activity, all Awards granted or other compensation paid by
the Company under the Plan, including any shares of Common Stock issued under any Award thereunder, will be subject to: (i) any compensation recapture policies established by the Board or the Committee from time to time and in effect at the
time of grant of the Award, and (ii) any compensation recapture policies to the extent required pursuant to any applicable law (including, without limitation, the Dodd-Frank Act) or the rules and
regulations of any national securities exchange on which the shares of Common Stock are then traded. 
 13.22 Reformation.

 If any provision regarding Detrimental Activity or any other provision set forth in the Plan or an Award agreement is found by any
court of competent jurisdiction or arbitrator to be invalid, null, void, or unenforceable or to be excessively broad as to duration, activity, geographic application, or subject, such provision or provisions shall be construed by limiting or
reducing them to the extent legally permitted so as to be enforceable to the maximum extent compatible with then applicable law. 
 13.23
Electronic Communications. 
 Notwithstanding anything herein or in any Award to the contrary, any Award agreement, notice of
exercise of an Exercisable Award, or other document or notice required or permitted by the Plan or an Award that is required to be delivered in writing may, to the extent determined by the Committee, be delivered and accepted electronically.
Signatures also may be electronic if permitted by the Committee. The term “written agreement” as used in the Plan shall include any document that is delivered or accepted electronically. 

13.24 Agreement. 

As a condition to the grant of an Award, if requested by the Company and the lead underwriter of any public offering of the Common
Stock (the “Lead Underwriter”), a Participant shall irrevocably agree, and by acceptance of an Award shall irrevocably be deemed to have agreed, not to sell, contract to sell, grant any option to purchase, transfer the
economic risk of ownership in, make any short sale of, pledge, or otherwise Transfer or dispose of, any interest in any Common Stock or any securities convertible into, derivative of, or exchangeable or exercisable for Common Stock, or any other
rights to purchase or acquire Common Stock (except Common Stock included in such public offering or acquired on the public market after such offering) during such period of time following the effective date of a registration statement of the Company
filed under the Securities Act that the Lead Underwriter shall specify (the “Lock-up Period”). The Participant shall further agree to sign such documents as may be requested by the Lead
Underwriter to effect the foregoing and agree that the Company may impose stop-transfer instructions with respect to Common Stock acquired pursuant to an Award until the end of such Lock-up Period. 
 13.25 Transition Period. 

The Plan has been adopted by the Board before the occurrence of a Registration Date. The Plan is intended to constitute a plan described in
Treasury Regulation § 1.162-27(f)(1). 

  
 34 

 ARTICLE XIV 

EFFECTIVE DATE OF PLAN 

The Plan was adopted by the Board on December 13, 2017, to be effective on the date of effectiveness of the registration statement on
Form S-1 filed by the Company with the Securities and Exchange Commission for the initial public offering of the Common Stock (the “Effective Date”). The Plan was approved by the stockholders of the Company on
December 18, 2017. 
 ARTICLE XV 

TERM OF PLAN 
 No
Award shall be granted on or after the tenth anniversary of the earlier of (a) the Effective Date or (b) the date of stockholder approval of the Plan, provided that Awards granted before the tenth anniversary of the Plan’s
adoption by the Board may extend beyond that date in accordance with the terms of the Plan. Following the Transition Period, the Company may seek stockholder re-approval of the Performance Criteria to the
extent that such stockholder approval is obtained no later than the first stockholder meeting that occurs in the fifth year following the year in which such stockholders previously approved the Performance Criteria. Awards (other than Stock Options
or stock appreciation rights) may be based on such Performance Criteria to qualify for the “performance-based compensation” exception under Section 162(m) of the Code. 

  
 35 

 SOLID BIOSCIENCES INC. 

2018 OMNIBUS INCENTIVE PLAN 

EXHIBIT A: PERFORMANCE CRITERIA 

Performance goals established for purposes of the grant or vesting of performance-based Awards of
Restricted Stock, Other Stock-Based Awards, or Performance-Based Cash Awards that are intended to be
“performance-based” under Section 162(m) shall be based on one or more of the following performance criteria (“Performance Criteria”): 

 

	 	(1)	enterprise value or value creation targets; 

  

	 	(2)	income or net income; operating income; net operating income or net operating income after tax; operating profit or net operating profit; 

 

	 	(3)	cash flow, including but not limited to, from operations or free cash flow; 

  

	 	(4)	specified objectives with regard to limiting the level of increase in all or a portion of bank debt or other long-term or short-term public
or private debt or other similar financial obligations, or other capital structure improvements, which may be calculated net of cash balances or other offsets and adjustments as may be established by the Committee; 

 

	 	(5)	net sales, revenues, net income, or earnings before income tax or other exclusions; 

  

	 	(6)	operating margin, return on operating revenue, or return on operating profit; 

  

	 	(7)	return measures (after tax or pre-tax), including return on capital employed, return on invested capital, return on equity, return on assets, return on net assets;

  

	 	(8)	market capitalization, earnings per share, fair market value of the shares of the Company, franchise value (net of debt), economic value added; 

 

	 	(9)	total stockholder return or growth in total stockholder return (with or without dividend reinvestment); 

  

	 	(10)	financing and other capital raising transactions; 

  

	 	(11)	proprietary investment results; 

  

	 	(12)	estimated market share; 

  

	 	(13)	expansion of sales in additional geographies or markets; 

  

	 	(14)	expense management/control or reduction (including, without limitation, compensation and benefits expense); 

  
 Ex. A-1 

	 	(15)	customer satisfaction; 

  

	 	(16)	technological improvements/implementation, new product innovation; 

  

	 	(17)	collections and recoveries; 

  

	 	(18)	property or asset purchases; 

  

	 	(19)	litigation and regulatory resolution/implementation goals; 

  

	 	(20)	leases, contracts, or financings (including renewals, overhead, savings, G&A, and other expense control goals); 

  

	 	(21)	risk management/implementation; 

  

	 	(22)	development and implementation of strategic plans or organizational restructuring goals; 

  

	 	(23)	development and implementation of risk and crisis management programs; compliance requirements and compliance relief; productivity goals; workforce management and succession planning goals; 

 

	 	(24)	employee satisfaction or staff development; 

  

	 	(25)	formations of joint ventures or partnerships or the completion of other similar transactions intended to enhance revenue or profitability or to enhance its customer base; 

 

	 	(26)	licensing or partnership arrangements; 

  

	 	(27)	progress of partnered programs and partner satisfaction; 

  

	 	(28)	progress of internal research or development programs; 

  

	 	(29)	submission of a new drug application (“NDA”) or the approval of the NDA by the U.S. Food and Drug Administration (“FDA”); 

 

	 	(30)	submission of an investigational new drug application (“IND”) or the approval of the IND by the FDA; 

  

	 	(31)	submission of a therapeutic biologics license application (“BLA”) or the approval of the BLA by the FDA; 

  

	 	(32)	submission to, or approval by, a foreign regulatory body of an applicable filing or a product; 

  

	 	(33)	strategic partnerships or transactions (including in-licensing and out-licensing of intellectual property; 

  
 Ex. A-2 

	 	(34)	achievement of a launch of a new drug; 

  

	 	(35)	initiation or completion of a clinical trial phase; 

  

	 	(36)	implementation or completion of critical projects; 

  

	 	(37)	achievement of specified milestones in the discovery and development of one or more of the Company’s products; 

  

	 	(38)	achievement of specified milestones in the commercialization of one or more of the Company’s products; 

  

	 	(39)	achievement of specified milestones in the manufacturing of one or more of the Company’s products; 

  

	 	(40)	achievement of specified regulatory milestones relating to one or more of the Company’s products; or 

  

	 	(41)	completion of a merger, acquisition, or any transaction that results in the sale of all or substantially all of the stock or assets. 

All Performance Criteria may be based upon the attainment of specified levels of the Company (or Affiliate, division, other operational unit,
business segment, or administrative department of the Company or any Affiliate) performance under one or more of the measures described above and may be measured relative to the performance of other corporations (or an affiliate, subsidiary,
division, other operational unit, business segment, or administrative department of another corporation or its affiliates). Any goal may be expressed as a dollar figure, on a percentage basis (if applicable), or on a per share basis, and goals may
be either absolute, relative to a selected peer group or index, or a combination of both. To the extent permitted under Section 162(m), (including compliance with any requirements for stockholder approval), the Committee may: (i) designate
additional business criteria on which the Performance Criteria may be based or (ii) adjust, modify, or amend the aforementioned business criteria. 

Except as otherwise determined by the Committee in the applicable Award agreement, the measures used in Performance Criteria set under the
Plan shall be determined in accordance with generally accepted accounting principles (“GAAP”) and in a manner consistent with the methods used in the Company’s regular reports on Forms
10-K and 10-Q, without regard to any of the following unless otherwise determined by the Committee consistent with the requirements of Section 162(m)(4)(C) of the
Code and the regulations thereunder: 
 (a) all items of gain, loss, or expense for the fiscal year or other applicable Performance Period
that are related to special, unusual, or non-recurring items, events, or circumstances affecting the Company (or Affiliate, division, other operational unit, business segment, or administrative department of
the Company or any Affiliate) or the financial statements of the Company (or Affiliate, division, other operational unit, business segment, or administrative department of the Company or any Affiliate); 

  
 Ex. A-3 

 (b) all items of gain, loss, or expense for the fiscal year or other applicable Performance
Period that are related to (i) the disposal of a business or discontinued operations or (ii) the operations of any business acquired by the Company (or Affiliate, division, other operational unit, business segment, or administrative
department of the Company or any Affiliate) during the fiscal year or other applicable Performance Period; and 
 (c) all items of gain,
loss, or expense for the fiscal year or other applicable Performance Period that are related to changes in accounting principles or to changes in applicable law or regulations. 

To the extent any Performance Criteria are expressed using any measures that require deviations from GAAP, such deviations shall be at the
discretion of the Committee as exercised at the time the Performance Criteria are set and, following the Transition Period, to the extent permitted under Section 162(m). 

  
 Ex. A-4 

 SOLID BIOSCIENCES INC. 

2018 OMNIBUS INCENTIVE PLAN 

EXHIBIT B: UNITED KINGDOM ADDENDUM 

 

	1.	Purpose 

  

	1.1	The purpose of this United Kingdom Addendum to the Plan (the “UK Addendum”) is to enable the Committee to grant Awards (being Stock Options, Restricted Stock, Other
Stock-Based Awards, or Performance-Based Cash Awards) to certain employees and full-time directors of the Company who are based
in the United Kingdom (“UK”) only. 

  

	1.2	Awards granted pursuant to the UK Addendum will be non-tax advantaged for UK tax purposes and, to the extent relevant, Awards are granted pursuant to an “employee share
scheme” for the purposes of the Financial Services and Markets Act 2000. 

  

	2.	Definitions 

 Any terms not defined in this UK Addendum will have the meaning set
out in Article II of the Plan. 
  

	3.	Terms 

 Awards granted pursuant to the UK Addendum shall be governed by the terms
of the Plan, subject to any such amendments set out below and by the terms of the individual Award agreement entered into between the Company and the Participant. 
  

	4.	Withholding Obligations 

  

	4.1	The Participant shall be accountable for any income tax and, subject to the following provisions, national insurance liability that is chargeable on any assessable income deriving from the grant, vesting, exercise,
transfer, or cancellation (whether for consideration or otherwise) of an Award, or in respect of any additional share or cash consideration acquired as a result of distribution of a dividend, or otherwise in respect of the exercise of an Award. In
respect of such assessable income, the Participant shall indemnify the Company and (at the direction of the Company) any Affiliate which is or may be treated as the employer of the Participant in respect of the following (together, the
“Tax Liabilities”): 

  

	 	(a)	any income tax liability that falls to be paid to Her Majesty’s Revenue and Customs (“HMRC”) by the Company (or the relevant employing Affiliate) under the PAYE system as it applies to
income tax under the Income Tax (Earnings and Pensions) Act 2003 (“ITEPA”) and the Pay As You Earn (“PAYE”) regulations referred to therein; and 

  
 Ex. B-1 

	 	(b)	any national insurance liability that falls to be paid to HMRC by the Company (or the relevant employing Affiliate) under the PAYE system as it applies for national insurance purposes under the Social Security
Contributions and Benefits Act 1992 and regulations referred to therein, including: 

  

	 	(i)	all the employee’s primary Class 1 national insurance contributions; and 

  

	 	(ii)	to the extent permitted by law, all of the employer’s secondary Class 1 national insurance contributions. 

  

	4.2	Pursuant to the indemnity referred to in clause 4.1 above, the Participant shall make such arrangements as the Company requires to meet the cost of the Tax Liabilities, including, at the direction of the Company,
any of the following: 

  

	 	(a)	making a cash payment of an appropriate amount to the relevant employing company whether by cheque, banker’s draft, or deduction from salary in time to enable the Company to remit such amount to HMRC before the
14th day following the end of the month in which the event giving rise to the Tax Liabilities occurred; 

  

	 	(b)	appointing the Company as agent or attorney for the sale of sufficient Shares acquired pursuant to the exercise of any Stock Options or pursuant to the grant, exercise, or vesting of an Award to cover the Tax
Liabilities and authorising the payment to the relevant company of the appropriate amount (including all reasonable fees, commissions, and expenses incurred by the relevant employing company in relation to such sale) out of the net proceeds of sale
of such Shares; or 

  

	 	(c)	to the extent permitted by law, entering into: 

  

	 	(i)	an agreement that allows the Participant’s employer to recover the whole or any portion of any employer’s secondary Class 1 National Insurance Contributions in respect of the vesting or exercise of the Award
from the Participant; or 

  

	 	(ii)	an election whereby the employer’s liability for secondary Class 1 national insurance contributions is transferred to the Participant on terms set out in the election, as approved by HMRC. 

 

	4.3	The failure by a Participant to make arrangements in line with clause 4.2 above at the request of the Company shall result in the vesting of such Award (other than an Exercisable Award) or the exercise of such
Exercisable Award (as applicable) being ineffective, null, and void. 

  

	5.	Section 431 Elections 

 Where Shares to be acquired on the exercise or
vesting of an Award are considered (at the sole discretion of the Company) to be “restricted securities” for the purposes of Part 7 of ITEPA, it is a condition of exercise that the Participant (if so directed by the Company) enter into a
joint election with the Company (or, if different, the relevant employing Affiliate) pursuant to Section 431 of ITEPA electing that the market value of the shares to be acquired on the exercise or vesting of the Award be calculated as if the
Shares were not “restricted securities.” 

  
 Ex. B-2EX-10.11

 Exhibit 10.11 

CONFIDENTIAL TREATMENT REQUESTED 
 PATENT
LICENSE AGREEMENT 
 This Agreement is effective as of March 10, 2016 (the “EFFECTIVE DATE”), between Solid GT, LLC (“LICENSEE”)
having the address in Article 12 below, and the Regents of the University of Michigan, a constitutional corporation of the state of Michigan (“MICHIGAN”) having the address in Article 12 below. LICENSEE and MICHIGAN hereby agree as
follows: 
 ARTICLE 1 – DEFINITIONS 

“AFFILIATE” means any corporation, partnership, joint venture or other entity of which a majority of the voting stock or other equity ownership
thereof is owned or controlled by, or under common control with, LICENSEE, or which owns or controls a majority of the voting stock or other equity ownership of LICENSEE. 

“FIELD OF USE” means all uses. 
 “FIRST
COMMERCIAL SALE” means the first SALE through a bona fide arms length transaction of any LICENSED PRODUCT or first commercial use of any LICENSED PROCESS by LICENSEE or a SUBLICENSEE, excluding the SALE of a LICENSED PRODUCT or use of a
LICENSED PROCESS for use in trials, as a sample or that is of temporary availability. 
 “LICENSED PROCESS(ES)” means any process or method that,
but for this Agreement, would comprises an infringement of (including contributory or inducement) a VALID CLAIM in the country in which any such process or method is used or performed, or (b) employs a LICENSED PRODUCT. 

“LICENSED PRODUCT(S)” means any product that: (a) but for this Agreement, comprises an infringement of (including contributory or inducement) a
VALID CLAIM in the country in which any such product or product part is made, used, imported, offered for SALE or sold; or (b) is manufactured by using a LICENSED PROCESS or is employed to practice a LICENSED PROCESS. 

“MICHIGAN,” as used in Articles 9 and 10, shall include its Regents, officers, employees, students, and agents. 

“NET SALES” means the amount billed or invoiced, and if any amount is not billed or invoiced, the amounts actually received, on Sales, however
characterized, by LICENSEE and/or SUBLICENSEES of LICENSED PRODUCTS and uses of LICENSED PROCESSES, less the following deductions (but only to the extent such deductions are otherwise included in NET SALES and are not obtained in view of other
consideration received by LICENSEE): 
 (a) cash discounts actually granted to customers in such invoices for SALE of LICENSED PRODUCTS, but
only in amounts customary in the trade; 

  
 [XXX] CERTAIN INFORMATION
HAS BEEN OMITTED AND FILED SEPARATELY WITH THE COMMISSION. 
 CONFIDENTIAL TREATMENT HAS BEEN REQUESTED WITH RESPECT TO THE OMITTED PORTIONS.

 CONFIDENTIAL TREATMENT REQUESTED 

 

 (b) sales taxes, tariff duties and/or use taxes separately stated in such bills or invoices
with reference to particular SALES and actually paid by LICENSEE or SUBLICENSEE to a governmental unit; 
 (c) actual freight expenses
between LICENSEE or SUBLICENSEE and customers, to the extent such expenses are not charged to or reimbursed by customers; or 
 (d) amounts
actually refunded or credited on returns. 
 Where LICENSEE or SUBLICENSEE receives any consideration other than cash for such transactions,
fair market cash value for such consideration, to be agreed upon by the parties hereto, shall be included in NET SALES. Where a product or activity is a LICENSED PRODUCT or LICENSED PROCESS hereunder due to contributory infringement or inducement of
infringement, NET SALES shall include SALES of the product or process that constitutes a direct infringement of the PATENT RIGHTS. NET SALES shall not include LICENSED PRODUCT used for pre-clinical or clinical
trials, post-marketing trials, samples and indigent patient programs or any other uses of LICENSED PRODUCT not ordinarily included as part of NET SALES for royalty determination purposes. 

A sale or transfer to an AFFILIATE or SUBLICENSEE for re-sale by such AFFILIATE or SUBLICENSEE shall
not be considered a sale for the purpose of this provision but the resale by such AFFILIATE or SUBLICENSEE shall be a sale for such purposes. Any amounts received LICENSEE, an AFFILIATE or SUBLICENSEE in exchange for LICENSED PRODUCTS or LICENSED
PROCESSES transferred or provided to any person or entity for use in testing, clinical trials, or as marketing samples to develop or promote the LICENSED PRODUCTS are not included in the definition of NET SALES. 

“PATENT RIGHTS” means MICHIGAN’S legal rights under the patent laws of the United States or relevant foreign countries for all of the
following: 
 (a) the following United States and foreign patent(s) and/or patent application(s), and divisionals, continuations, continuations-in-part (only to the extent that such claims are fully supported under U.S. patent laws by another patent or application in the PATENT RIGHTS), and foreign
counterparts of the same: 
 [XXX]; and 

[XXX]; and 
 (b) any renewals,
reexaminations, substitutes, supplementary protection certificates and extensions of these patents, and any corresponding foreign counterparts of the same. 

“ROYALTY PERIOD(S)” means the six-month periods ending on the last days of June and December each year. 

  
 2 

  
 [XXX] CERTAIN INFORMATION
HAS BEEN OMITTED AND FILED SEPARATELY WITH THE COMMISSION. 
 CONFIDENTIAL TREATMENT HAS BEEN REQUESTED WITH RESPECT TO THE OMITTED PORTIONS.

 CONFIDENTIAL TREATMENT REQUESTED 

 

 “SALE” means sale, rental, or lease, however characterized, and SOLD means the past tense of SALE.

 “SUBLICENSEE(S)” means any person or entity in writing sublicensed, or granted an option for a sublicense, by LICENSEE under this Agreement.

 “TERRITORY” means all of the countries of the world. 

“VALID CLAIM” means (i) a claim in an issued and unexpired patent included in the PATENT RIGHTS that: (a) has not been held unenforceable,
unpatentable or invalid by a decision of a court or other governmental agency of competent jurisdiction, and not subject to appeal, (b) has not been admitted to be invalid or unenforceable through reissue or disclaimer or otherwise,
(c) has not been lost through an interference, reexamination, or reissue proceeding; or (ii) a pending claim of a pending patent application included in the PATENT RIGHTS that has not been abandoned or finally rejected without the
possibility of appeal or refiling and that has been pending for less than seven years from its priority date. 
 ARTICLE 2 – GRANT OF
LICENSE 
 2.1 MICHIGAN hereby grants to LICENSEE an exclusive license under the PATENT RIGHTS, with the right to grant sublicenses, both subject to the
terms and conditions of this Agreement, in the FIELD OF USE and the TERRITORY to make, have made, import, use, market, offer for sale and sell LICENSED PRODUCTS and to practice LICENSED PROCESSES. 

2.2 Without limiting any other rights it may have, MICHIGAN specifically reserves the right for it and its affiliates to practice and have practiced the
PATENT RIGHTS for non-commercial research, public service, internal (including clinical) and/or educational purposes, and the right to grant the same limited
non-commercial rights to other non-profit research institutions. For avoidance of doubt, sponsored research on behalf of
for-profit entities shall be deemed to be commercial. 
 2.3 This Agreement shall extend until expiration of the
last to expire of the PATENT RIGHTS, unless sooner terminated as provided in another specific provision of this Agreement. 
 2.4 LICENSEE agrees that
LICENSED PRODUCTS used, leased or sold in the United States shall be manufactured substantially in the United States. 
 2.5 The licenses granted in this
Agreement are subject to any rights required to be granted under prior research or sponsorship agreements, or retained by the U.S. government, for example in accordance with Chapter 18 of Title 35 of U.S.C.
200-212 and the regulations thereunder (37 CFR Part 401), when applicable. LICENSEE agrees to comply in all respects, and shall provide MICHIGAN with all reasonably requested information and cooperation for
MICHIGAN to comply with applicable provisions of the same and any requirements of any agreements between MICHIGAN and any agency of the U.S. government that provided funding for the subject matter covered by the PATENT RIGHTS. 

  
 3 

  
 [XXX] CERTAIN INFORMATION
HAS BEEN OMITTED AND FILED SEPARATELY WITH THE COMMISSION. 
 CONFIDENTIAL TREATMENT HAS BEEN REQUESTED WITH RESPECT TO THE OMITTED PORTIONS.

 CONFIDENTIAL TREATMENT REQUESTED 

 

 ARTICLE 3 - CONSIDERATION 

3.1 LICENSEE shall pay the following to MICHIGAN: 

(a) License Issue Fee. A License Issue Fee equal to [XXX], due within fourteen (14) days from the complete execution of this
Agreement. 
 (b) Annual Maintenance Fee. An Annual Maintenance Fee equal to [XXX], due within fourteen (14) days of the second
(2nd) anniversary of the EFFECTIVE DATE, and within fourteen (14) days of each subsequent anniversary of the EFFECTIVE DATE. The Annual Maintenance Fee shall not be due in any calendar year
that the LICENSEE pays Minimum Annual Royalties as described in Section 3.1 (e) or Running Royalties as described in Section 3.1 (b) in an amount equal to or greater than Minimum Annual Royalties. 

(b) Running Royalties. Running Royalties equal to [XXX] of NET SALES. If LICENSEE makes any SALES to any AFFILIATE at a price less than
the regular price charged to other parties, the Running Royalties payable to MICHIGAN shall be computed on the basis of the regular price charged to other parties. 

(c) Sublicensing Fees. Sublicensing Fees equal to a percentage of any revenue not based on product sales that LICENSEE or SUBLICENSEES
(or a designee) is due from or receives from SUBLICENSEES or assignees in consideration for rights under or relating to the PATENT RIGHTS (e.g., license issue fees, maintenance or annual minimum fees, milestone payments, other royalties), but
excluding, (a) amounts received for the purchase of securities; (b) payments of loans or other debt obligations, (c) payments made as a reimbursement of costs incurred, such as for patent prosecution costs, (d) amounts received
to cover research and development activities related to actual or potential LICENSED PRODUCTS or LICENSED PROCESSES after the effective date of the sublicense agreement, and (e) amounts attributable to intellectual property other than the
LICENSED PATENTS, as follows: 
  

	 	1)	[XXX] if the sublicense is entered into on or after the EFFECTIVE DATE and before [XXX]; 

  

	 	2)	[XXX] if the sublicense is entered into at or after [XXX] and before [XXX]; and 

  

	 	3)	[XXX] if [XXX] into at or after [XXX]. 

 (d) Back Patent Costs. Within fourteen
(14) days from complete execution of this Agreement, LICENSEE shall pay MICHIGAN all of the Back Patent Costs which are [XXX] as of March 10, 2016. 

  
 4 

  
 [XXX] CERTAIN INFORMATION
HAS BEEN OMITTED AND FILED SEPARATELY WITH THE COMMISSION. 
 CONFIDENTIAL TREATMENT HAS BEEN REQUESTED WITH RESPECT TO THE OMITTED PORTIONS.

 CONFIDENTIAL TREATMENT REQUESTED 

 

 (e) Minimum Annual Royalties. Beginning with the FIRST COMMERCIAL SALE, Minimum Annual
Royalties are due for each calendar year within sixty (60) days following the end thereof. Minimum Annual Royalties shall be credited against Running Royalties (and, if paid first, Running Royalties shall be credited against Minimum Annual
Royalties) due on NET SALES made during the calendar year for which the Minimum Annual Royalties apply. Minimum Annual Royalties paid in excess of Running Royalties shall not be creditable to amounts due for future years. The Minimum Annual Royalty
is [XXX]. 
 (f) Milestone Payments for LICENSED PRODUCT as follows (for the avoidance of doubt, none of these Milestone Payments
shall be required to be paid more than once): 
 (a) [XXX] 

(b) [XXX] 
 (c) [XXX] 

(d) [XXX] 
 Milestone payments are non refundable
and non-creditable against royalties. 
 (g) Change of Control. Within thirty (30) days after
any CHANGE OF CONTROL, LICENSEE shall pay to MICHIGAN a two million dollar ($2,000,000.00) fee (“CHANGE OF CONTROL FEE”). As used herein, “CHANGE OF CONTROL” shall mean: (a) any consolidation, merger, combination, reorganization
or other transaction in which LICENSEE is not the surviving entity, irrespective of whether LICENSEE is maintained as an AFFILIATE or subsidiary of the new controlling entity, or dissolved and absorbed into the new controlling entity; or (b) any
transaction or series of related transactions in which the shares of stock or other equity interests of LICENSEE constituting in excess of fifty percent (50%) of the voting power of LICENSEE are exchanged for or converted into other stock or
securities, cash and/or any other property; or (c) a sale or other disposition of all or substantially all of the assets of the LICENSEE. 
 3.2 LICENSEE is
not obligated to pay multiple royalties if any LICENSED PRODUCT or LICENSED PROCESS is covered by more than one VALID CLAIM or the same LICENSED PRODUCT is covered by VALID CLAIMS in two or more countries. If LICENSEE or its AFFILIATES or
SUBLICENSEE enters into a license agreement with a third party that LICENSEE reasonably determines is necessary and procured for the commercialization of a LICENSED PRODUCT or LICENSED PROCESS and according to such license agreement a royalty must
be paid to the third party by LICENSEE or its AFFILIATE or SUBLICENSEE based upon commercialization of a LICENSED PRODUCT or LICENSED PROCESS, then the royalty otherwise payable to MICHIGAN pursuant to Section 3.1 may be reduced by [XXX] of the
applicable third party royalty; provided that, in no instance shall the royalty payable to MICHIGAN by LICENSEE ever be reduced below [XXX] of the otherwise applicable royalty. 

  
 5 

  
 [XXX] CERTAIN INFORMATION
HAS BEEN OMITTED AND FILED SEPARATELY WITH THE COMMISSION. 
 CONFIDENTIAL TREATMENT HAS BEEN REQUESTED WITH RESPECT TO THE OMITTED PORTIONS.

 CONFIDENTIAL TREATMENT REQUESTED 

 

 3.3 Royalty payments shall be made to “The Regents of the University of Michigan” in United States
dollars. Payments drawn directly on a U.S. bank may be made by either check to the address in Article 12 or by wire transfer. Any payment drawn on a foreign bank or foreign branch of a U.S. bank shall be made only by wire transfer. Wire transfers
shall be made in accordance with the following or any other instructions as may be specified by MICHIGAN. In computing royalties, LICENSEE shall convert any revenues it receives in foreign currency into its equivalent in United States dollars at the
most recent exchange rate published in the Wall Street Journal on the last business day of the ROYALTY PERIOD during which such payments are received by LICENSEE, or at such other exchange rate as the parties may agree to in writing. 

3.4 Royalty payments shall be made on a semi-annual basis with submission of the reports required by Article 4. All amounts due under this Agreement,
including amounts due for the payment of patent expenses, shall, if overdue, be subject to a charge of interest [XXX] until payment, [XXX] above the prime rate in effect at the JP Morgan Chase Bank, N.A. or its successor bank on the due date (or at
the highest allowed rate if a lower rate is required by law) or [XXX], whichever is greater. The payment of such interest shall not foreclose MICHIGAN from exercising any other rights it may have resulting from any late payment. LICENSEE shall
reimburse MICHIGAN for the costs, including reasonable attorney fees, for expenses paid in order to collect any amounts overdue more than 120 days. 
 3.5
All payments made under this Agreement are and shall be non-refundable. MICHIGAN shall have no obligation whatsoever to pay, return, credit, or refund any amounts paid hereunder, except as may be specifically
provided herein. By way of example only, notwithstanding the deductions permitted to NET SALES, MICHIGAN shall have no obligation to pay any amounts to LICENSEE even if such deductions should result in a negative amount for NET SALES in any given
ROYALTY PERIOD. 
 3.6 The payments required to be paid by LICENSEE to MICHIGAN pursuant to this agreement may be paid with deduction for taxes withheld
under the LICENSEE’s or, if applicable, its SUBLICENSEE’s applicable domestic law. LICENSEE will reasonably assist MICHIGAN to obtain full benefit of any applicable tax treaty to reduce the amount of such withheld taxes. MICHIGAN shall be
responsible for the payment of all taxes, duties, levies, and other charges imposed by any taxing authority with respect to the royalties payable to MICHIGAN under this agreement. LICENSEE may withhold or deduct any portion of the payments due to
MICHIGAN required under applicable law or regulation of any government entity or authority. LICENSEE shall cooperate reasonably with MICHIGAN in the event MICHIGAN elects to assert, at its own expense, any exemption from any such tax or deduction.

 ARTICLE 4 - REPORTS 
 4.1 Until the
FIRST COMMERCIAL SALE, by July 31 of each year LICENSEE shall provide to MICHIGAN a written annual report that includes reports on progress since the prior annual report and general future plans regarding: research and development, regulatory
approvals, manufacturing, sublicensing, marketing and SALES. Further, LICENSEE shall 

  
 6 

  
 [XXX] CERTAIN INFORMATION
HAS BEEN OMITTED AND FILED SEPARATELY WITH THE COMMISSION. 
 CONFIDENTIAL TREATMENT HAS BEEN REQUESTED WITH RESPECT TO THE OMITTED PORTIONS.

 CONFIDENTIAL TREATMENT REQUESTED 

 

 
specifically report to MICHIGAN the FIRST COMMERCIAL SALE within sixty (60) days thereafter, and provide a brief description of the products or services subject of the FIRST COMMERCIAL SALE,
and terms thereof. 
 4.2 After the FIRST COMMERCIAL SALE, LICENSEE shall provide semi-annual reports to MICHIGAN. Specifically, as of the end of each
ROYALTY PERIOD (and delivered within sixty (60) days after such ROYALTY PERIOD closes, including the close of the ROYALTY PERIOD immediately following any termination of this Agreement), LICENSEE shall report to MICHIGAN for the applicable
ROYALTY PERIOD: 
 (a) number of LICENSED PRODUCTS sold, leased, or distributed, however characterized, by LICENSEE and each SUBLICENSEE.

 (b) NET SALES, excluding the deductions provided therefor, of LICENSED PRODUCTS SOLD by LICENSEE and all SUBLICENSEES. 

(c) a description and accounting for all LICENSED PROCESSES SOLD, by LICENSEE and all SUBLICENSEES included in NET SALES, excluding the
deductions therefor. 
 (d) deductions applicable as provided in the definition for NET SALES above, and an explanation of the rationale(s)
therefor. 
 (e) Sublicense Fees due on payments from SUBLICENSEES under Paragraph 3.1 above, including supporting figures. 

(f) foreign currency conversion rate and calculations (if applicable) and total royalties due. 

(g) each milestone under Article 3 or Article 5 having a deadline during the ROYALTY PERIOD, and a specific identification of whether or not it
was achieved. 
 (h) for each sublicense or amendment thereto completed in the particular ROYALTY PERIOD (including agreements under which
LICENSEE will have LICENSED PRODUCTS made by a third party): names, addresses, and U.S.P.T.O. Entity Status (as discussed in Paragraph 4.5) of such SUBLICENSEE; the date of each agreement and amendment; the territory of the sublicense; the scope of
the sublicense; and the nature, timing and amounts of all fees, royalties to be paid thereunder. 
 (i) progress on research and development,
regulatory approvals, manufacturing, sublicensing, marketing and SALES, and general plans for the future. 
 (j) the date of first SALE of
LICENSED PRODUCTS (or results of LICENSED PROCESSES) in each country and the circumstances thereof. 
 LICENSEE shall include the amount of all payments
due, and the various calculations used to arrive at those amounts, including the quantity, description (nomenclature and type designation as described in Paragraph 4.3 below), country of manufacture and country of SALE or use of LICENSED PRODUCTS
and LICENSED PROCESSES. 

  
 7 

  
 [XXX] CERTAIN INFORMATION
HAS BEEN OMITTED AND FILED SEPARATELY WITH THE COMMISSION. 
 CONFIDENTIAL TREATMENT HAS BEEN REQUESTED WITH RESPECT TO THE OMITTED PORTIONS.

 CONFIDENTIAL TREATMENT REQUESTED 

 

 If no payment is due, LICENSEE shall so report to MICHIGAN that no payment is due. Failure to provide reports
as required under this Article 4 shall be a material breach of this Agreement. LICENSEE agrees to reasonably cooperate with MICHIGAN regarding any questions it may have relating to compliance with this Agreement, for example to discuss the
information in reports. 
 4.3 LICENSEE shall promptly establish and consistently employ a system of specific nomenclature and type designations for
LICENSED PRODUCTS and LICENSED PROCESSES to permit identification and segregation of various types where necessary, and shall require the same of SUBLICENSEES. 

4.4 LICENSEE shall keep, and shall require SUBLICENSEES to keep, true and accurate records containing data reasonably required for the computation and
verification of payments due under this Agreement. LICENSEE shall and it shall require all SUBLICENSEES and those making LICENSED PRODUCTS to: (a) open such records for inspection upon reasonable notice during business hours, and no more than
once per year, at MICHIGAN’s sole expense, by either MICHIGAN auditor(s) or an independent certified accountant selected by MICHIGAN and reasonably acceptable to LICENSEE, for the purpose of verifying the amount of payments due, and shall
provide information to MICHIGAN to facilitate such inspection; and (b) retain such records for six (6) years from date of origination. 
 The
terms of this Article shall survive any termination of this Agreement. MICHIGAN is responsible for all expenses of such inspection, except that if any inspection reveals an underpayment greater than [XXX] of royalties due MICHIGAN, then LICENSEE
shall pay all expenses of that inspection and the amount of the underpayment and interest to MICHIGAN within thirty (30) days of written notice thereof. LICENSEE shall also reimburse MICHIGAN for reasonable expenses required to collect the
amount underpaid. 
 4.5 So that MICHIGAN may pay the proper U.S. Patent and Trademark Office fees relating to the PATENT RIGHTS, if LICENSEE, any
AFFILIATE, or any SUBLICENSEE (including optionees) does not quality as a “Small Entity” under U.S. patent laws, LICENSEE shall notify MICHIGAN immediately. The parties understand that the changes to LICENSEE’s, AFFILIATE’s,
SUBLICENSEE’s, or optionees’ businesses that might affect entity status include: acquisitions, mergers, hiring of a total of more than 500 total employees, sublicense agreements, and sublicense options. 

ARTICLE 5 - DILIGENCE 
 5.1 LICENSEE shall
use commercially reasonable efforts to bring one or more LICENSED PRODUCTS to market, and/or one or more LICENSED PROCESSES to commercial use, through a diligent program for utilizing the PATENT RIGHTS and to continue diligent marketing efforts
throughout the life of this Agreement, in each case consistent with prudent business practices and judgment. LICENSEE has the responsibility to do all that is legally required and commercially reasonable to obtain and retain any governmental
approvals to manufacture and/or sell LICENSED PRODUCTS and/or use LICENSED PROCESSES for all 

  
 8 

  
 [XXX] CERTAIN INFORMATION
HAS BEEN OMITTED AND FILED SEPARATELY WITH THE COMMISSION. 
 CONFIDENTIAL TREATMENT HAS BEEN REQUESTED WITH RESPECT TO THE OMITTED PORTIONS.

 CONFIDENTIAL TREATMENT REQUESTED 

 

 
relevant activities of LICENSEE and SUBLICENSEES. If the commercialization of multiple LICENSED PRODUCTS or LICENSED PROCESSES is commercially reasonable, then the requirement of this paragraph
shall apply to all such LICENSED PRODUCTS and/or LICENSED PROCESSES. Further, for the sake of clarity, LICENSEE must make commercially reasonable amounts or levels of LICENSED PRODUCTS and/or LICENSED PROCESSES available. 

5.2 Without limiting Paragraph 5.1, LICENSEE agrees to reach the following commercialization and research and development milestones for the LICENSED PRODUCTS
and LICENSED PROCESSES (together the “MILESTONES”) by the following dates: 
 1) [XXX] 

2) [XXX] 
 3) [XXX] 

4) [XXX] 
 For the purposes of this Agreement,
initiation of a clinical trial shall mean that date upon which the first patient or subject is treated with a LICENSED PRODUCT under a protocol approved by an appropriate drug regulatory agency with a therapeutic agent or process that has been
manufactured according to Good Manufacturing Practices (GMP) guidelines provided by the relevant regulatory agency. 
 5.3 LICENSEE must achieve each
MILESTONE on or before the deadline dates indicated above. LICENSEE shall notify MICHIGAN within thirty (30) days after each such deadline as to whether or not such MILESTONE was met. If LICENSEE fails to meet any MILESTONE under this Article
by the date of any MILESTONE deadline, LICENSEE will be deemed to be in material breach of this Agreement, and MICHIGAN may terminate the Agreement effective on ninety (90) days’ written notice, unless LICENSEE achieves the MILESTONE
within this ninety (90) day period. 
 ARTICLE 6 - SUBLICENSING 

6.1 LICENSEE shall notify MICHIGAN in writing of every sublicense agreement and each amendment thereto within thirty (30) days after their execution, and
indicate the name of the SUBLICENSEE, the territory of the sublicense, the scope of the sublicense, and the nature, timing and amounts of all fees and royalties to be paid thereunder, and whether or not the SUBLICENSEE has greater or fewer than 500
employees. Upon request, LICENSEE shall provide MICHIGAN with a copy of sublicense agreements. 
 6.2 LICENSEE shall not receive from SUBLICENSEES anything
of value other than cash payments in consideration for any sublicense under this Agreement, without the express prior written permission of MICHIGAN. 

  
 9 

  
 [XXX] CERTAIN INFORMATION
HAS BEEN OMITTED AND FILED SEPARATELY WITH THE COMMISSION. 
 CONFIDENTIAL TREATMENT HAS BEEN REQUESTED WITH RESPECT TO THE OMITTED PORTIONS.

 CONFIDENTIAL TREATMENT REQUESTED 

 

 6.3 Each sublicense granted by LICENSEE under this Agreement shall provide for its termination upon
termination of this Agreement. Each sublicense shall terminate upon termination of this Agreement unless LICENSEE has previously assigned its rights under the sublicense to MICHIGAN and MICHIGAN has agreed at its sole discretion in writing to such
assignment. 
 6.4 LICENSEE shall require that all sublicenses: (a) be consistent with the terms and conditions of this Agreement; (b) contain the
SUBLICENSEE’S acknowledgment of the disclaimer of warranty and limitation on MICHIGAN’s liability, as provided by Article 9 below; and (c) contain provisions under which the SUBLICENSEE accepts duties at least equivalent to those
accepted by the LICENSEE in the following Paragraphs: 4.4 (duty to keep records), 10.1 (duty to defend, hold harmless, and indemnify MICHIGAN), 10.3 (duty to maintain insurance), 13.4 (duty to properly mark LICENSED PRODUCTS with patent notices),
and 13.6 (duty to restrict the use of MICHIGAN’s name). 
 ARTICLE 7 - PATENT APPLICATIONS AND MAINTENANCE 

7.1 MICHIGAN shall have the right to control all aspects maintaining the patents that form the basis for the PATENT RIGHTS, including administrative
reexaminations and reviews, disputes (including litigation) regarding inventorship and derivation, and interferences. LICENSEE shall fully cooperate with MICHIGAN in activities relating to the PATENT RIGHTS, including said activities. Upon
MICHIGAN’s request, to the extent permitted by law, LICENSEE shall cooperate with MICHIGAN in applying for patent term extension for any and all patents included in the PATENT RIGHTS. LICENSEE and MICHIGAN will mutually agree on the
jurisdictions in which to seek such patent protection. 
 7.2 MICHIGAN shall notify LICENSEE of all information received by MICHIGAN relating to maintenance
of the PATENT RIGHTS, and shall make reasonable efforts to allow LICENSEE to review, comment, and advise upon such information. LICENSEE shall hold such information confidential and to use the information only for the purpose of advancing
MICHIGAN’s PATENT RIGHTS. 
 7.3 LICENSEE shall reimburse MICHIGAN for all fees and costs relating to the activities described in this Article;
provided, however, that LICENSEE shall not be responsible to reimburse such fees and cost relating to any country in which LICENSEE has not agreed to seek patent protection. Such reimbursement shall be made within thirty (30) days of receipt of
MICHIGAN’s invoice and shall be subject to the interest and other requirements specified in Article 4 above. 
 ARTICLE 8 -
ENFORCEMENT 
 8.1 Each party shall promptly advise the other in writing of any known acts of potential infringement of the PATENT RIGHTS by another
party. LICENSEE has the first option to police the PATENT RIGHTS against infringement by other parties within the TERRITORY and the FIELD OF USE, including those prior to the EFFECTIVE DATE. LICENSEE shall not file any suit without (a) first
performing a thorough, diligent investigation of the merits of such suit, including with respect to the validity and enforceability of the PATENT RIGHTS; (b) there being reasonable legal and economic bases for doing so; and (c) notifying
MICHIGAN twenty 

  
 10 

  
 [XXX] CERTAIN INFORMATION
HAS BEEN OMITTED AND FILED SEPARATELY WITH THE COMMISSION. 
 CONFIDENTIAL TREATMENT HAS BEEN REQUESTED WITH RESPECT TO THE OMITTED PORTIONS.

 CONFIDENTIAL TREATMENT REQUESTED 

 

 
days before any such filing. This right to police includes filing, prosecuting, and settling all infringement actions at its expense, except that LICENSEE shall make any such settlement only with
the advice and consent of MICHIGAN. LICENSEE has the right to file suit using counsel of its choosing, subject to MICHIGAN’s approval, which shall not be unreasonably withheld or delayed. LICENSEE may grant to third parties the right to enforce
hereunder, but only with the express written permission of MICHIGAN. 
 8.2 If LICENSEE has complied with Paragraph 8.1, MICHIGAN shall provide reasonable
assistance to LICENSEE with respect to such actions, but only if LICENSEE promptly reimburses MICHIGAN for out-of-pocket expenses incurred in connection with any such
assistance rendered at LICENSEE’s request or reasonably required by MICHIGAN, including but not limited to expenses incurred in complying with discovery duties. MICHIGAN retains the right to participate, with counsel of its own choosing and at
its own expense, in any action under this Article. LICENSEE shall defend, indemnify and hold harmless MICHIGAN with respect to any claims asserted by an alleged infringer reasonably related to the enforcement of the PATENT RIGHTS under this Article,
including but not limited to antitrust counterclaims and claims for recovery of attorney fees. 
 8.3 MICHIGAN and its employees have a vital interest in
lawsuits relating to the validity and enforceability of the PATENT RIGHTS. If a third party files a suit, including as a counterclaim, alleging that any of the PATENT RIGHTS is invalid or unenforceable, then the parties shall jointly control the
defense of such claim. Each party shall consult with the other with respect to the defense of such claim, and shall reasonably consider the other party’s input. In furtherance of such joint control, at the onset of such claim and as reasonable
during the pendency of any such claim, the parties shall meet and confer in good faith to set a plan for handling the defense thereof. The parties expect that in general (a) LICENSEE will have the right to lead daily activities, including but
not limited to discovery, relating to the defense and (b) the parties would make joint filings. Notwithstanding, in the event that the parties cannot agree on how to proceed with respect to such claim, MICHIGAN shall have the right to control
the defense thereof on either a temporary or permanent basis. LICENSEE shall be responsible for the reasonable costs and fees associated with the activities under this Paragraph 8.3. The parties shall consider reasonable controls on costs and fees
as part of an aforementioned meet and confer with respect to the handling of the defense. Notwithstanding, if a third party asserts jurisdiction for any such action solely as the result of acts of MICHIGAN, then MICHIGAN shall be responsible for
such reasonable costs and fees. LICENSEE shall have the right to offset [XXX] of any fees it is responsible for under this Section 8.3 from payments it is required to make to MICHIGAN under Section 3.1 hereof. 

8.4 If LICENSEE or MICHIGAN recovers damages in patent litigation or settlement thereof, the award shall be applied first to satisfy LICENSEE’s (to the
extent not offset in accordance with Section 8.3) and MICHIGAN’s reasonable expenses and legal fees for the litigation. The remaining balance shall be divided equally between LICENSEE and MICHIGAN. This provision shall control the division
of revenues where a sublicense, covenant not to sue, or assignment of rights is granted as part of a settlement of such lawsuit (including prospective rights). 

  
 11 

  
 [XXX] CERTAIN INFORMATION
HAS BEEN OMITTED AND FILED SEPARATELY WITH THE COMMISSION. 
 CONFIDENTIAL TREATMENT HAS BEEN REQUESTED WITH RESPECT TO THE OMITTED PORTIONS.

 CONFIDENTIAL TREATMENT REQUESTED 

 

 ARTICLE 9 - NO WARRANTIES; LIMITATION ON MICHIGAN’S LIABILITY 

9.1 MICHIGAN makes no representations or warranties that any claim within the PATENT RIGHTS is or will be held valid, patentable, or enforceable, or that the
manufacture, importation, use, offer for SALE, SALE or other distribution of any LICENSED PRODUCTS or LICENSED PROCESSES will not infringe upon any patent or other rights. 

9.2 MICHIGAN MAKES NO REPRESENTATIONS, EXTENDS NO WARRANTIES OF ANY KIND, EITHER EXPRESS OR IMPLIED, INCLUDING BUT NOT LIMITED TO THE IMPLIED
WARRANTIES OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE, AND ASSUMES NO RESPONSIBILITIES WHATEVER WITH RESPECT TO DESIGN, DEVELOPMENT, MANUFACTURE, USE, SALE OR OTHER DISPOSITION BY LICENSEE OR SUBLICENSEES OF
LICENSED PRODUCTS OR LICENSED PROCESSES. LICENSEE AND SUBLICENSEES ASSUME THE ENTIRE RISK AS TO PERFORMANCE OF LICENSED PRODUCTS AND LICENSED PROCESSES. 

9.3 In no event shall MICHIGAN be responsible or liable for any direct, indirect, special, incidental, or consequential damages or lost profits or other
economic loss or damage with respect to LICENSED PRODUCTS LICENSED PROCESSES, or the PATENT RIGHTS to LICENSEE, SUBLICENSEES or any other individual or entity regardless of legal or equitable theory. The above limitations on liability apply even
though MICHIGAN may have been advised of the possibility of such damage. 
 9.4 LICENSEE shall not make any statements, representations or warranties
whatsoever to any person or entity, or accept any liabilities or responsibilities whatsoever from any person or entity that are inconsistent with any disclaimer or limitation included in this Article 9. 

ARTICLE 10 - INDEMNITY; INSURANCE 
 10.1
LICENSEE shall defend, indemnify and hold harmless and shall require SUBLICENSEES to defend, indemnify and hold harmless MICHIGAN for and against any and all claims, demands, damages, losses, and expenses of any nature (including attorneys’
fees and other litigation expenses), resulting from, but not limited to, death, personal injury, illness, property damage, economic loss or products liability, including errors and omissions, arising from or in connection with, any of the following:
(1) Any manufacture, use, SALE or other disposition by LICENSEE, SUBLICENSEES or transferees of LICENSED PRODUCTS or LICENSED PROCESSES; (2) The use by any person of LICENSED PRODUCTS made, used, sold or otherwise distributed by LICENSEE
or SUBLICENSEES; and (3) The use or practice by LICENSEE or SUBLICENSEES of any invention or computer software related to the PATENT RIGHTS. 
 10.2
MICHIGAN is entitled to participate at its option and expense through counsel of its own selection, and may join in any legal actions related to any such claims, demands, damages, losses and expenses under Paragraph 10.1 above. LICENSEE shall not
settle any such legal action with an admission of liability of MICHIGAN without MICHIGAN’s written approval. 

  
 12 

  
 [XXX] CERTAIN INFORMATION
HAS BEEN OMITTED AND FILED SEPARATELY WITH THE COMMISSION. 
 CONFIDENTIAL TREATMENT HAS BEEN REQUESTED WITH RESPECT TO THE OMITTED PORTIONS.

 CONFIDENTIAL TREATMENT REQUESTED 

 

 10.3 Prior to any distribution or commercial use of any LICENSED PRODUCT or use of any LICENSED PROCESS by
LICENSEE, LICENSEE shall purchase and maintain in effect commercial general liability insurance, product liability insurance, and errors and omissions insurance which shall protect LICENSEE and MICHIGAN with respect to the events covered by
Paragraph 10.1, and LICENSEE shall require the same of any SUBLICENSEE. Each such insurance policy must provide reasonable coverage for all claims with respect to any LICENSED PROCESS used and any LICENSED PRODUCTS manufactured, used, sold, licensed
or otherwise distributed by LICENSEE — or, in the case of a SUBLICENSEE’s policy, by said SUBLICENSEE — and must specify MICHIGAN as an additional insured. LICENSEE shall furnish certificate(s) of such insurance to MICHIGAN, upon
request. 
 10.4 In no event shall either party hereunder be liable to the other for any special, indirect, or consequential damages of any kind whatsoever
resulting from any breach or default of this Agreement. 
 ARTICLE 11 - TERM AND TERMINATION 

11.1 If LICENSEE ceases to operate its business, or if it files a petition in bankruptcy, has an involuntary petition in bankruptcy filed against LICENSEE
that is not dismissed within sixty days after the filing thereof, make a general assignment for the benefit of creditors or liquidates or dissolves, this Agreement shall immediately terminate upon MICHIGAN’s attempt to deliver a termination
notice to the address for notices provided herein. If LICENSEE makes or attempts to make an assignment for the benefit of creditors, or if proceedings in voluntary or involuntary bankruptcy or insolvency are instituted on behalf of or against
LICENSEE, or if a receiver or trustee is appointed for the property of LICENSEE, this Agreement shall automatically terminate. LICENSEE shall notify MICHIGAN of any such event mentioned in this Paragraph as soon as reasonably practicable, and in any
event within five days after any such event. 
 11.2 If LICENSEE fails to make any payment due to MICHIGAN, other than amounts subject to a bona fide
dispute, upon thirty (30) days’ written notice by MICHIGAN, this Agreement shall automatically terminate unless MICHIGAN specifically extends such date in writing or such unpaid amount is paid to MICHIGAN within such thirty (30) day
period. Such termination shall not foreclose MICHIGAN from collection of any amounts remaining unpaid or seeking other legal relief. 
 11.3 Upon any
material breach or default of this Agreement by LICENSEE (other than as specifically provided herein, the terms of which shall take precedence over the handling of any other material breach or default under this Paragraph), MICHIGAN has the right to
terminate this Agreement effective on ninety (90) days’ written notice to LICENSEE. Such termination shall become automatically effective upon expiration of the thirty-day period unless LICENSEE
cures the material breach or default before the period expires. 
 11.4 LICENSEE has the right to terminate this Agreement at any time on sixty
(60) days’ written notice to MICHIGAN if LICENSEE prior to the termination date: 
 (a) pays all amounts due MICHIGAN through the
effective date of the termination; 
 (b) submits a final report of the type described in Paragraph 4.2; 

  
 13 

  
 [XXX] CERTAIN INFORMATION
HAS BEEN OMITTED AND FILED SEPARATELY WITH THE COMMISSION. 
 CONFIDENTIAL TREATMENT HAS BEEN REQUESTED WITH RESPECT TO THE OMITTED PORTIONS.

 CONFIDENTIAL TREATMENT REQUESTED 

 

 (c) returns any patent documentation (including that exchanged under Article 7) and any other
confidential or trade-secret materials provided to LICENSEE by MICHIGAN in connection with this Agreement, or, with prior approval by MICHIGAN, destroys such materials, and certifies in writing that such materials have all been returned or
destroyed; and 
 (d) suspends its manufacture, use and SALE of the LICENSED PROCESS(ES) and LICENSED PRODUCT(S). 

11.5 Upon any termination of this Agreement, and except as provided herein to the contrary, all rights and obligations of the parties hereunder shall cease,
except any previously accrued rights and obligations and further as follows: (a) obligations to pay royalties and other sums, or to transfer equity or other consideration, accruing hereunder up to the day of such termination, whether or not
this Agreement provides for a number of days before which actual payment is due and such date is after the day of termination and whether or not a required funding event or other stock transfer trigger has yet been met; (b) MICHIGAN’s
rights to inspect books and records as described in Article 4, and LICENSEE’s obligations to keep such records for the required time; 
 (c) any cause
of action or claim of LICENSEE or MICHIGAN accrued or to accrue because of any breach or default by the other party hereunder; (d) the provisions of Articles 1, 9, 10, and 13; and (e) all other terms, provisions, representations, rights
and obligations contained in this Agreement that by their sense and context are intended to survive until performance thereof by either or both parties. 

Termination by either party hereunder shall not alter or affect any other rights or relief that either party may be entitled to under law. 

11.6 Upon termination of this Agreement, if LICENSEE has filed patent applications or obtained patents to any modification or improvement to LICENSED PRODUCTS
or LICENSED PROCESSES within the scope of the PATENT RIGHTS, LICENSEE agrees upon request to enter into good faith negotiations with MICHIGAN or MICHIGAN’s future licensee(s) for the purpose of granting licensing rights to said modifications or
improvements in a timely fashion and under commercially reasonable terms. 
 11.7 If LICENSEE or a SUBLICENSEE, or any affiliate thereof, asserts the
invalidity or unenforceability of any claim included in the PATENT RIGHTS, including by way of litigation or administrative proceedings, either directly or through any other party, then MICHIGAN shall have the right to immediately terminate this
Agreement upon written notice to LICENSEE. 
 ARTICLE 12 - NOTICES 

12.1 Any notice, request, or report required or permitted to be given or made under this Agreement by either party is effective when mailed if sent by
recognized overnight carrier, certified or registered mail, or electronic mail followed by confirmation by U.S. mail, to the address set forth below or such other address as such party specifies by written notice given in conformity herewith. Any
notice, request, or report not so given is not effective until actually received by the other party. 

  
 14 

  
 [XXX] CERTAIN INFORMATION
HAS BEEN OMITTED AND FILED SEPARATELY WITH THE COMMISSION. 
 CONFIDENTIAL TREATMENT HAS BEEN REQUESTED WITH RESPECT TO THE OMITTED PORTIONS.

 CONFIDENTIAL TREATMENT REQUESTED 

 

			
	To MICHIGAN:	  	To LICENSEE:
		
	 Office of Technology Transfer
 University of
Michigan
 1600 Huron Parkway, 2nd Floor
 Ann Arbor, MI
48109-2590
	  	 Solid GT, LLC
 One Broadway

Cambridge, MA 02142
 Attention: Ilan Ganot, CEO

 ARTICLE 13 - MISCELLANEOUS PROVISIONS 

13.1 This Agreement shall be governed by and construed under the laws of the state of Michigan without regard for principles of choice of law, except that
questions affecting the construction and effect of any patent shall be determined by the law of the country in which the patent was granted. Any claims, demands, or actions asserted against MICHIGAN, its Regents, fellows, officers, employees or
agents shall only be brought in the Michigan Court of Claims. LICENSEE, its successors, and assigns consent to the jurisdiction of a court with applicable subject matter jurisdiction sitting in the state of Michigan with respect to any claims
arising under this agreement or the relationship between the parties. 
 13.2 MICHIGAN and LICENSEE agree that this Agreement sets forth their entire
understanding concerning the subject matter of this Agreement. The parties may amend this Agreement from time to time, such as to add new rights, but no modification will be effective unless both MICHIGAN and LICENSEE agree to it in writing. 

13.3 If a court of competent jurisdiction finds any term of this Agreement invalid, illegal or unenforceable, that term will be curtailed, limited or deleted,
but only to the extent necessary to remove the invalidity, illegality or unenforceability, and without in any way affecting or impairing the remaining terms. 

13.4 LICENSEE agrees to mark the LICENSED PRODUCTS sold in the United States with all applicable United States patent numbers as necessary to meet the
requirements of 35 U.S.C. 287 so that the full benefits of patent enforcement may be realized. All LICENSED PRODUCTS shipped to or sold in other countries shall be marked to comply with the patent laws and practices of the countries of manufacture,
use and SALE. 
 13.5 No waiver by either party of any breach of this Agreement, no matter how long continuing or how often repeated, is a waiver of any
subsequent breach thereof, nor is any delay or omission on the part of either party to exercise or insist on any right, power, or privilege hereunder a waiver of such right, power or privilege. In no event shall any waiver be deemed valid unless it
is in writing and signed by an authorized representative of each party. 
 13.6 LICENSEE shall, and shall require its affiliates to, refrain from using and
to require SUBLICENSEES to refrain from using the name of MICHIGAN or its employees in publicity or advertising without the prior written approval of MICHIGAN. Reports in scientific literature and presentations of joint research and development work
are not publicity. Notwithstanding this provision, without prior written approval of MICHIGAN, LICENSEE and SUBLICENSEES 

  
 15 

  
 [XXX] CERTAIN INFORMATION
HAS BEEN OMITTED AND FILED SEPARATELY WITH THE COMMISSION. 
 CONFIDENTIAL TREATMENT HAS BEEN REQUESTED WITH RESPECT TO THE OMITTED PORTIONS.

 CONFIDENTIAL TREATMENT REQUESTED 

 

 
may state publicly that LICENSED PRODUCTS and PROCESSES were developed by LICENSEE based upon an invention(s) developed at the University of Michigan and/or that the PATENT RIGHTS were licensed
from the University of Michigan. 
 13.7 LICENSEE agrees to comply with all applicable laws and regulations, including but not limited to all United States
laws and regulations controlling the export of commodities and technical data. LICENSEE shall be solely responsible for any violation of such laws and regulations involving LICENSEE or its SUBLICENSEES, and to defend, indemnify and hold harmless
MICHIGAN if any legal action of any nature results from any such violation. 
 13.8 The relationship between the parties is that of independent contractor
and contractee. Neither party is an agent of the other in connection with the exercise of any rights hereunder, and neither has any right or authority to assume or create any obligation or responsibility on behalf of the other. 

13.9 LICENSEE may not assign this Agreement without the prior written consent of MICHIGAN and shall not pledge any of the license rights granted in this
Agreement as security for any creditor. Any attempted pledge of any of the rights under this Agreement or assignment of this Agreement without the prior consent of MICHIGAN will be void from the beginning. No assignment by LICENSEE will be effective
until the intended assignee agrees in writing to accept all of the terms and conditions of this Agreement, and such writing is provided to MICHIGAN. Notwithstanding the foregoing, LICENSEE may, without MICHIGAN’s consent, assign its rights
under this Agreement to a purchaser of all or substantially all of LICENSEE’s business relating to the subject matter of this Agreement, so long as (a) LICENSEE is not in breach of this Agreement and (b) such assignee provides a
statement in writing to MICHIGAN that it agrees to accept all the terms and conditions of this Agreement (including obligations existing as of the time of such assignment) in the place of LICENSEE. 

13.10 If the registration, recordation, or reporting to a national or supranational agency of this Agreement, its terms, or assignment thereof is or becomes
required or advisable (e.g., as a prerequisite to enforceability of the Agreement in such nation), LICENSEE shall, at its expense, promptly undertake such action. LICENSEE shall provide prompt notice thereof to MICHIGAN along with copies of relevant
documentation. 

  
 16 

  
 [XXX] CERTAIN INFORMATION
HAS BEEN OMITTED AND FILED SEPARATELY WITH THE COMMISSION. 
 CONFIDENTIAL TREATMENT HAS BEEN REQUESTED WITH RESPECT TO THE OMITTED PORTIONS.

 CONFIDENTIAL TREATMENT REQUESTED 

 

 IN WITNESS WHEREOF, the parties hereto have executed this Agreement in duplicate originals by their duly
authorized officers or representatives. 
  

									
	 FOR LICENSEE:
 SOLID GT,
LLC
	 		 	FOR THE REGENTS OF THE UNIVERSITY OF MICHIGAN
					
	By	 	 /s/ Ilan Ganot
	 		 	By	 	 /s/ Ruth L. Rasor

		 	(authorized representative)	 		 		 	Ruth L. Rasor
	Printed Name	 	 Ilan Ganot
	 		 		 	 Managing Director of Licensing
 UM
Technology Transfer

	Title	 	 CEO
	 		 		 	
	Date	 	 3/11/16
	 		 	Date	 	 14 March 2016

  
 17 

  
 [XXX] CERTAIN INFORMATION
HAS BEEN OMITTED AND FILED SEPARATELY WITH THE COMMISSION. 
 CONFIDENTIAL TREATMENT HAS BEEN REQUESTED WITH RESPECT TO THE OMITTED PORTIONS.

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00278-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00278-of-00352.parquet"}]]